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ABSTRACT 
Acute microinjections of the GABA-agonist, muscimol, into the dor-
sal or median raphe nucleus of ether-anesthetized rats induced hyper-
kinesis as measured in photocell activity chambers. The median raphe 
nucleus is more sensitive to the effect of muscimol than the dorsal 
raphe nucleus. A dose-response analysis performed by injecting muscimol 
through cannulae chronically implanted in the dorsal or the median raphe 
nucleus of rats confirmed the greater sensitivity of the median raphe 
site. Intraperitoneal administration of the benzodiazepine, chlordiaze-
poxide, in a subataxic dose did not affect activity level, but enhanced 
the locomotor responses to low doses of muscimol injected into the 
median raphe nucleus. Conversely, intraperitoneal administration of a 
sub-convulsant dose of the GABA-antagonist, bicuculline, completely 
blocked the r~sponse to muscimol. 
Subsequently, dose-response analyses for the water soluble benzo-
diazepines, chlordiazepoxide, flurazepam, and midazolam were performed 
by injecting the drugs through cannulae chronically implanted in the 
median raphe nucleus of rats. Both midazolam and flurazepam produced 
hyperactivity which was most prominent within the first 30 minutes 
post-injection. Flurazepam, moreover, proved twice as potent as midaz-
olam. In contrast, chlordiazepoxide was without effect at any of the 
doses tested. 
xi 
~ext, animals received either saline or a sub-effective dose of 
flurazepam or midazolam into the median raphe nucleus 5 minutes prior to 
either a sub-effective dose of muscimol or saline. Only the combina-
tions of a benzodiazepine plus muscimol produced hyperactivity. These 
combinations, moreover, produced effects as robust as those of a four-
fold higher dose of muscimol alone. 
In another experiment, animals received either saline or bicucul-
line methiodide injections into the median raphe nucleus 5 minutes 
before they received a hyperactivity-inducing dose of muscimol. Bicu-
culline completely blocked the hyperactivity effects of muscimol. Ove-
rall, these data suggest that the hyperkinetic effects of intra-raphe 
muscimol injections are due to activation of GABA receptors within the 
midbrain raphe, rather than at distant sites. 
In a subsequent experiment, bilateral electrolytic destruction of 
the ventral tegmental nuclei of Gudden, which lie just dorsolateral to , 
the median raphe nucleus, produced an increase in baseline activity 
level, but failed to alter the median raphe muscimol dose-response rela-
tionship. 
Finally, forebrain serotonin was depleted by administering· 
5,7-dihydroxytryptamine intracerebrally. These lesions markedly attenu-
ated the hyperactivity response produced by muscimol injections into the 
median raphe nucleus. These data suggest that midbrain GABA neurons 
modulate activity level through a direct action on serotonergic neurons. 
xii 
CHAPTER I 
INTRODUCTION 
The benzodiazepines were introduced into clinical medicine in the 
early 1960's. They quickly became the most commonly prescribed class of 
pharmaceuticals. Today, some 20 years after their introduction, the 
benzodiazepines are used widely as sedative-hypnotic, anti-convulsant, 
anti-anxiety, muscle-relaxant and pre-anesthetic drugs. Since 1976, 
more than 100 million prescriptions for the benzodiazepines have been 
written annually in the United States alone (Harvey, 1980). 
There is a consensus that the benzodiazepines exert their beha-
vioral and physiological effects by facilitating the post-synaptic 
action of the inhibitory amino acid neurotransmitter, gamma-aminobu-
tyric acid (GABA; Haefely et al., 1975; Costa and Guidotti, 1979; 
Krogsgaard-Larsen and Arnt, 1980; Olsen, 1982). For the most part, GABA 
releasing cells constitute local circuit neurons, or interneurons, 
within a given brain structure. These GABA-ergic cells, which are dis-
tributed throughout the neuraxis, modify the operation of other neurons 
which often utilize a neurotransmitter other than GABA. GABA interneu-
rons thus modulate the inputs and outputs of a given brain region and, 
thereby, its function. As facilitators of GABA neurotransmission, it is 
r.ot surprising that the benzodiazepines can produce profound behavioral 
effects. 
1 
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It is the objective of the present work to elucidate the role of 
midbrain GABA and benzodiazepine receptors in the modulation of locomo-
tor activity, and to determine whether this regulatory function is medi-
ated by a serotonergic system. In order to provide a background for 
this research effort, the following topics will be reviewed: 1) the 
pharmacology of the benzodiazepines; 2) the behavioral effects of the 
benzodiazepines; 3) GABA and serotonin as neurotransmitters; 4) GABA-
benzodiazepine interactions; 5) serotonin -benzodiazepine interactions; 
and, 6) the modulation of midbrain raphe neurons by GABA and benzodiaze-
pine receptors. 
Benzodiazepines 
Chemistry 
The nucleus of the benzodiazepine molecule is depicted in Figure 1 
At the 7-position, electronegative groups enhance, and electropositive 
groups reduce potency. Substituents elsewhere in this ring decrease 
activity. A wide variety of moieties may occupy positions 1 to 3. A 
low electron density at the 4-nitrogen, provided by a double bond bet-
ween positions 4 and 5, or by an electron-withdrawing group at position 
4, is common to all clinically useful benzodiazepines. An electronega-
tive 2'-substituent (ortho) on the 5-phenyl moiety will enhance potency 
(Harvey, 1980). 
Substitutions have led to four basic classes of the benzodiaze-
pines (Figure 1): the 1) 2-keto- ; 2) triazolo- ; 3) 3-hydroxy- ; and, 
4) the 7-nitro- benzodiazepines. These different classes of benzodiaze-
3 
pines all possess anti-convulsant, anti-anxiety, sedative-hypnotic, and 
muscle-relaxant properties. It is the differences in their pharmacoki-
netics which largely determine their clinical application (Johnson and 
Rising, 1979; Breimer et al., 1980). A major problem associated with 
the 2-keto- benzodiazepines, which include the often prescribed seda-
tive-hypnotic, flurazepam, and the multipurpose drug, diazepam, is the 
production of long-acting (half-life 50 - 100 hours) active metabolites 
(Benet and Scheiner, 1980; Breimer et al., 1980). Certain benzodiaze-
pines, such as prazepam, chlorazepate, and possibly chlordiazepoxide, 
appear to serve as pro-drugs for the formation in vivo of active 
2-keto- metabolites (Curry and Whelpton, ~979). These compounds, thus, 
find clinical utility in the treatment of anxiety-neuroses where long-
term steady-state plasma levels of drug (or active metabolite) are desi-
rable (Baldessarini, 1980). A 7-nitro- group (as contained, for exam-
ple, in clonazepam; Figure 1) increases anti-convulsant activity CRall 
and Schleifer, 1980). Furthermore, the 7-nitro-benzodiazepines are 
reduced to inactive 7 -amino- derivatives, the parent compounds having 
half-lives ranging between 15 and 37 hours. The 
3-hydroxy-benzodiazepines have short half-lives (8. 5 - 15 hours), plus 
the advantage of being conjugated at the 3-position to form inactive 
glucuronide derivatives which are excreted directly (Benet and Scheiner, 
1980; Breimer et al., 1980). F.inally, the triazolo-benzodiazepines 
have very short half-lives (2.5 - 11 hours). They are oxidized to form 
compounds which do not cross the blood-brain barrier and are rapidly 
4 
FIGURE 1: Structures of benzodiazepine nucleus and subclasses. 
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excreted following oxidation (Johnson and Rising, 1979; Pieri et a1., 
1981). For more complete reviews of benzodiazepine structure-activity 
relationships, the reader is referred to Sternbach ( 1973), Greenblatt 
and Shader (1974), Johnson and Rising (1979), and Breimer et al. 
(1980). 
Pharmacological Properties 
In the present study, three different benzodiazepines have been 
employed. These drugs were selected primarily because they are all 
water soluble, but show distinct pharmacokinetic properties. We thus 
will concentrate on these agents, the structures of which are shown in 
Figure 2: 1) chlordiazepoxide; 2) flurazepam; and, 3) midazolam. 
Chlordiazepoxide· 
Chlordiazepoxide was the first benzodiazepine marketed as a "minor 
tranquilzer" or anxiolytic drug. It was synthesized in 1955 by Stern-
bach, and its sedative-hypnotic and anti-anxiety effects were discovered 
not long after (Greenblatt and Shader, 1974). Unstable in solution, 
preparations for parenteral administration must be freshly mixed and 
used immediately. When injected intravenously into mice, there is 
immediate uptake of radio labeled chlordiazepoxide into brain, heart, 
kidney, liver, and skeletal muscle. Brain radioactivity at first is 
more concentrated in neocortex and thalamus, but within 10 minutes after 
injection the label is distributed evenly throughout the brain (Placidi 
7 
FIGURE 2: Structures of benzodiazepines used in present study. 
8 
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and Cassaro, 1968). Within several hours, 
9 
the label becomes 
concentrated in excretory organs. 
Chlordiazepoxide is extensively (87-88%) bound to plasma proteins, 
especially albtimin (Greenblatt and Shader, 1974). The half-life of 
chlordiazepoxide, itself, is approximately 10 hours. This figure, 
however, is somewhat misleading. The parent drug is converted to 
centrally-active metabolites, such as desmethyl-chlordiazepoxide and 
demoxepam, the latter compound having a reported half-life of up to 95 
hours (Greenblatt and Shader, 1974). In fact, the anxiolytic effect of 
chlordiazepoxide in humans is better correlated with the steady-state 
concentrations of these metabolites than with the plasma level of 
chlordiazepoxide itself (Lin.and Friedel, 1979). 
Flurazepam 
Flurazepam, a 2-keto-benzodiazepine, is very rapidly metabolized, 
having a plasma half-life of less than 2 hours (Greenblatt and Shader, 
1974). As is the case with chlordiazepoxide, flurazepam is converted to 
active metabolites. Although flurazepam, itself, is centrally active, 
the desamino- and desalkyl- metabolites are an order of magnitude more 
potent, and reach higher plasma levels than the parent compound (Hase-
gawa and Hatsubara, 1975; Harvey, 1980). The elimination half-life of 
the desamino- compound approximates 20 hours, while that of the desal-
kyl- metabolite approaches 100 hours (Breimer, 1977). 
10 
Midazolam 
Midazolam is a triazolo-benzodiazepine, which is characterized by 
an imidazole ring fused to positions 1 and 2 of the diazepine ring. The 
compound first was synthesized by Walser and collaborators (1978). The 
imidazole ring confers a high stability in aqueous solution and a short 
duration of action (Pieri et al., 1981). After intravenous administra-
tion the plasma half-life of midazolam ranges from 1.3 - 2.5 hours (Lau-
ven et al., 1981; Amrein et al., 1981). The major route of metabolism 
is demethylation to form alpha-hydroxymidazolam, which subsequently is 
conjugated with glucuronic acid. In addition, oxidation can occur at 
position 4 yielding 4-hydroxymidazolam and alpha,4-dihydroxy- midazolam 
(Walser et al., 1978.) The non-conjugated metabolites are markedly less 
potent than the parent compound in vivo, primarily due to their poor 
penetration of the blood-brain barrier (Pieri et al., 1981). Midazolam 
has a rapid onset of action (Heizman and Ziegler, 1981; Crevoisier et 
al., 1981.) This property, combined with its short duration of action, 
solubility in aqueous vehicle, and lack of active metabolites, make 
midazolam ideal for animal studies in which repeated daily injections 
are needed. 
Benzodiazepines and Behavior 
In view of the clinical effects of the benzodiazepines, it is not 
surprising that these compounds produce striking behavioral changes when 
administered to laboratory animals. In order to facilitate this review, 
studies concerning the behavioral effects of the benzodiazepines will be 
11 
discussed under one of the following rubrics: 1) appetitive behavior, 
2) avoidance behavior, 3) conflict behavior, 4) aggressive behavior, and 
5) locomotor activity. 
Appetitive Behavior 
The effects of the benzodiazepines on appetitive behavior are cri-
tically dependent upon the nature of the reward and the specific experi-
mental paradigm employed. In general, two different primary positive 
reinforcers (reward) have been used: a) consummatory reward, and b) 
electrical brain stimulation reward (BSR; Olds and Milner, 1954). To 
date, no consistent effects of benzodiazepines on responding for consum-
matory reward (for example, food or water) have been demonstrated (for 
excellent reviews, see Gray, 1977; and, Morley, 1980). With regard to 
responding for BSR, the benzodiazepines have been reported both to faci-
litate and to depress operant responding. In ieneral, low doses of the 
more potent anxiolytic benzodiazepines, such as diazepam and chlordiaze-
poxide, enhance responding for BSR (Olds, 1966; Panksepp et al., 1970; 
Wauquier, 1976), while sedative-hypnotic benzodiazepines, such as nitra-
zepam, produce a depression of response (Wauquier, -1976). In our own 
laboratory, we have noted a response enhancement following low doses 
(1.0 - 2.0 mg/kg, intraperitoneally) of midazolam (Sainati and Lorens, 
unpublished). The duration of the chlordiazepoxide- induced response 
enhancement greatly exceeds the presence of detectable amounts of chlor-
diazepoxide in serum (Wauquier, 1974; Lorens and Sainati, 1978). This 
probably is due to the conversion of chlordiazepoxide to active metabol-
12 
ites having very long durations of action (see above). One possible 
explanation for the benzodiazepine-induced response enhancement is that 
these and other drugs with abuse liability may release an endorphin 
whose effect on opiate receptors mediates the drug-induced alterations 
in BSR (Lorens, 1976; Stein, 1978; Lorens and Sainati, 1978). 
A drug with abuse liability in humans might be expected to be 
self-administered by laboratory animals. Although more difficult to 
establi&h than with opioids and stimulants, both oral and intravenous 
self-administration of benzodiazepines has been obtained (Harris et 
al., 1968; Findley et al., 1972; Davis et al., 1976; Walton and Deutsch, 
1979). These findings suggest that in addition to their effects on ope-
rant responding for BSR or consummatory reward, the benzodiazepines 
themselves have a positively reinforcing property. 
In contrast to the primary reinforcement hypothesis both Stein et 
al. (1977) and Wauquier (1976; 1979) have postulated that the facilita-
tory effects of the benzodiazepines on BSR may be due to a release from 
a punishing component of the stimulation. Benzodiazepine-induced beha-
vioral facilitation is seen most clearly in situations where rewarded 
behavior is suppressed by punishment (Wauquier, 1979). Although the 
anatomical substrates which mediate BSR have yet to be deliniated, the 
medial forebrain bundle appears to play an important role (Olds et al., 
1960; Lorens, 1976). According to Stein and coworkers (1977), BSR is 
mediated by catecholamine systems in the brain. Indeed, nor adrenergic 
fibers from the locus coeruleus [(A-6, in the classification of Dahlst-
13 
rom and Fuxe, 1964)], and dopaminergic fibers from the substantia nigra 
(A-9) and ventral tegmental area of Tsai (A-10), do ascend in the medial 
forebrain bundle (Lindvall and Bjorklund, 1978; Moore and Bloom, 1978; 
Bloom and Moore, 1979). Although some evidence suggests that dopamine 
neurons are important in the mediation of BSR, it appears that noradren-
ergic systems do not play a critical role (Fibiger, 1978). Ascending 
5-HT fibers, originating in the mesencephalic dorsal and median raphe 
nuclei, also have been found in the medial forebrain bundle (Azmitia and 
Segal, 1978). The ascending 5-HT systems have been implicated as form-
ing a component of a "punishment system" (Wise et al., 1972; Stein et 
al., 1973). The inhibition of this system theoretically would produce a 
release from punishment and a resultant enhancement in responding. 
Avoidance Behavior 
Passive Avoidance 
Passive avoidance is a term used to describe the learned suppres-
sion of approach behavior toward a particular place or stimulus. For 
example, following receipt of electrical foot shock for entering a 
designated area of a testing apparatus, the animal learns to refrain 
from returning to that section of the apparatus. Such a paradigm 
involves spatial discrimination. The benzodiazepines tend to impair 
passive avoidance acquisition and retention (Gray, 1977). Such effects 
have been seen with relatively high doses of chlordiazepoxide (7.5 - 60 
mg/kg) and diazepam (6-24 mg/kg) in both rats and mice (Fuller, 1970; 
14 
Morrison and Stephenson, 1970; Kumar, 1971; Oishi et al., 1972). In 
mice a similar disruption of passive avoidance retention has been 
reported following the ·administration of diazepam (10 mg/kg), lorazepam 
(20 mg/kg) and flurazepam (1.0 mg/kg) (Jensen et al., 1979). 
Active Avoidance 
Active avoidance is a general term used to describe experimental 
paradigms in which the animal must emit an operant response in order to 
avoid an aversive stimulus, such as an electric shock to the feet. 
Active avoidance paradigms may involve spatial (for example, the animal 
must move from one part of a test apparatus to another in order to avoid 
an electric shock) or non-spatial [for example, lever-pressing as in the 
paradigm of Sidman (1953)] operants (Gray, 1977). 
One-Way Active Avoidance 
In one-way active avoidance procedures, the subject is required 
always to move in one same direction to avoid an aversive stimulus. 
Thus, the spatial cues in the animal's surroundings become conditioned 
stimuli (CS). In most one-way avoidance test situations, benzodiaze-
pines have little effect on acquisition of the task, but do tend to 
reduce the response latency (Gray, 1977). 
15 
Two-Way Active Avoidance 
In two-way (shuttlebox) active avoidance, the animal is placed in 
one side of a two-compartment chamber. A warning signal (CS) is pre-
sented. At a given time (for example, 5 seconds) after the onset of the 
cs, the animal receives an unconditioned stimulus, electrical footshock, 
until it escapes to the other side of the apparatus. On the next trial, 
the process is repeated, only now the animal must return to the side 
where it originally was shocked. This represents a conflict between 
active and passive avoidance (Gray, 1977) because the subject naturally 
will be reluctant to return to the side from which it just fled. 
Accordingly, treatments which disrupt an animal's ability to utilize 
spatial cues may facilitate two-way avoidance acquisition. 
The facilitatory effect of chlordiazepoxide on shuttlebox perfor-
mance in rats and mice is well known (Fuller, 1970; Iwahara, 1971; Gray, 
1977; Sansone and Vetulani, 1980). In general, this facilitation is 
seen only after high doses, that is, those sufficient to suppress spon-
taneous locomotor activity (for example, 8.0 - 20 mg/kg). In our labo-
ratory, chlordiazepoxide in doses of 4.0 - 8.0 mg/kg tends to facilitate 
two-way avoidance acquisition during 50 massed trials, but this effect 
rarely reaches statistical significance (Sainati and Lorens, unpub-
lished). This finding is in agreement with observations made by Takao-
ri's group (1969), who reported that there is a tremendous variability 
in the performance of control animals even among littermates from the 
same strain. Midazolam (2. 0 - 4. 0 mg/kg), while failing to improve 
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acquisition of the two-way avoidance task, does increase the number of 
spontaneous inter-trial barrier crossings (Sainati and Lorens, unpub-
lished)· 
Sidman Avoidance 
Sidman avoidance paradigms represent a non-spatial avoidance task 
(Gray, 1977). Briefly, the subject is placed in a chamber outfitted 
with a manipulandum (Skinner box) and an electrifiable grid floor 
through which shocks are programmed to occur at regular intervals unless 
the subject performs the appropriate response (for example, lever-press-
ing). With a proper response, the animal can postpone the next shock 
for a certain period of time (Sidman, 1953; Heise and Boff, 1962). In 
general, low doses of benzodiazepines facilitate avoidance responding, 
especially . in animals whose performance is poor in the non-drugged 
state. High doses, in contrast, suppress avoidance behavior especially 
in animals with good performance in the non-drugged state (Gray, 1977). 
Similar results have been obtained for chlordiazepoxide, diazepam (Big-
nami et al.' 1971), nitrazepam (Takaori et al., 1969), tempazepam (Lon-
goni et al., 1973), flurazepam (Randall and Kappell, 1973), and midaz-
olam (Pieri et al., 1981). Gray (1977) and Bignami et al. (1971) 
suggest that the benzodiazepines improve performance in the Sidman avoi-
dance paradigm by reducing the suppressant effects of the apparatus cues 
associated with the shock. This hypothesis renders the Sidman avoidance 
paradigm a type of "conflict" test, as will be discussed below. 
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Conflict Behavior 
Of the psychopharmacological techniques available for studying the 
effects of anti-anxiety agents (for review see Bignami, 1976), among the 
most routinely employed are those involving operant conditioning techni-
ques in a Skinner box (Gray, 1977; Sepinwall and Cook, 1978). Such 
methods have achieved popularity because experimental animals can be 
used as their own controls, owing to the stability of baseline data in 
trained animals (Cook and Sepinwal1, 1975a). The conflict paradigm of 
Geller and Seifter (1960; 1962) has been used widely to study the 
effects of anxiolytics in laboratory animals. Briefly, this procedure 
involves a schedule in which periods of intermittent food reinforcement 
are alternated with periods during which continuous food reinforcement 
is available, but in combination with footshock punishment. This 
creates in the animal an approach- avoidance "conflict." Another "con-
flict" procedure is the lick-suppression test of Vogel and coworkers 
(1971), which consists of suppression of drinking by shocks administered 
through the drinking tube. The benzodiazepines, along with other clini-
cally effective anxiolytics (for example, meprobamate), enhance respond-
ing for food reward during the punished (conflict) segment, but not dur-
ing the non-punished segment. Diazepam, chlordiazepoxide, oxazepam, 
flurazepam, nitrazepam, flunitrazepam and midazolam, as well as other 
benzodiazepines, share this property (Geller et al., 1962; Margules and 
Stein, 1968; Stein et al., 1973; Gray, 1977; Sepinwall and Cook, 1978; 
Lippa et al., 1979; Malick and Enna, 1979; Pieri et al., 1981). These 
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drugs possess little analgesic potency (Bignami, 1976), and classical 
analgesics, such as morphine, possess little anti-conflict activity 
(Sepinwall and Cook, 1978). 
The notion that the anti-conflict effect of the benzodiazepines 
represents an animal model for predicting the antianxiety property of a 
compound in humans is strongly supported by the nearly perfect correla-
tion between the minimum effective doses of various anxiolytics in rat 
anti-conflict tests and the average daily clinically effective dose for 
the treatment of human anxiety neuroses (Cook and Sepinwall, 19 7 Sb; 
Lippa et al., 1978). The correlation between receptor binding potency 
and rat anti-conflict potency for various benzodiazepines also is excel-
lent (Hohler and Okada, 1977a; Sepinwall and Cook, 1980). Moreover, the 
anti-conflict property of the benzodiazepines has· been demonstrated in 
every species tested to date (Sepinwall and Cook, 1978). 
Aggression 
In various animal models of aggression, the benzodiazepines, as 
well as non-benzodiazepine anxiolytics, selectively decrease aggressive 
behavior in a number of species (Gray, 1977; Harvey, 1980). The experi-
mental paradigms employed have included experimenter provocation, elec-
tric shock, and isolation-induced aggression (Delgado, 1973; Christmas 
and Maxwell, 1970; Valzelli, 1973). It has been reported, however, that 
rat muricidal behavior is enhanced following benzodiazepine administra-
tion (Harvey, 1980). One possible explanation for this apparent paradox 
is the hypothesis of Hoffmeister and Wuttke (1969) that the benzodiaze-
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pines diminish defensive aggression, but enhance offensive aggression. 
Fighting induced by footshock or isolation would represent defensive 
aggression, whereas muricide would represent offensive aggression (pre-
dation). 
Locomotor Activity 
The effects of the benzodiazepines and other minor tranquilizers 
on spontaneous locomotor activity are dose-dependent (Greenblatt and 
Shader, 1974). At low doses, activity remains at baseline level, while 
at high doses, toxicity ensues and activity is reduced (Marriott and 
Spencer, 1965; Christmas and -Maxwell, 1970; Hughes, 1972). Intermediate 
doses tend to increase activity level. The effects of a given dose, 
however, are highly variable even within a given species. In rats, 
activity-enhancing doses of chlordiazepoxide range between 5.0 and 30 
mg/kg; the effective doses for diazepam and nitrazepam are between 0.5 
and 5.0 mg/kg (Greenblatt and Shader, 1974). Flurazepam tends to 
enhance locomotor activity in doses from 1.0 to 10 mg/kg (File and Hyde, 
1979; Crawley, 1981). Midazolam has been reported to enhance activity 
in lighted Animex chambers, but only after the dose of 5.0 mg/kg (Pieri 
et al., 1981). 
When evaluating the effect of any drug on locomotor activity, it 
is essential to pay particular attention to the experimental conditions 
employed. Rats and mice will approach a novel environment cautiously 
and tend to choose a familiar environment when given a choice (Green-
blatt and Shader, 1974; File and Hyde, 1979). It is important, thus, to 
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know whether the animal is familiar or unfamiliar with the test situa-
tion (Marriott and Spencer, 1965; Christmas and Maxwell, 1970; Hughes, 
1972). There are many reports of increases in exploratory behavior fol-
lowing benzodiazepine administration (Greenblatt and Shader, 1974), or 
of increased preference for a novel setting over a familiar one (Mar-
riott and Spencer, 1965; Hughes, 1972; File and Hyde, 1979; File, 1980; 
Crawley, 1981). 
Inasmuch as rats are nocturnal animals, the lighting conditions of 
the experimental surrounding also have an important influence on the 
locomotor response to a drug. Although the benzodiazepines, in suba-
taxic doses, tend to increase locomotor activity in a lighted arena 
(Marriott and Spencer, 1965; Christmas and Maxwell, 1970; Hughes, 1972), 
they have little effect on activity level when measured in dark photo-
cell cages (Krsiak et al., 1970; Pieri et al., 1981). This difference 
could be explained by the hypothesis that novel, lighted arenas are more 
fear or anxiety-producing, so that the anxiolytic benzodiazepines can 
release a fear-induced suppression of locomotor activity. 
Summary 
The benzodiazepines are an important class of drugs with several 
clinical applications. Recently it has become clear that the benzo-
diazepines also are "abused", or "recreationally" used, substances, 
often in combination with ethanol and/or the barbiturates. The benzo-
diazepines appear to have positively reinforcing effects in that they 
are self-administered by animals and man (Woods, 197?), and can enhance 
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responding for brain·stimulation reward. The benzodiazepines also 
dis inhibit punished behaviors. This is most clearly demonstrated in 
experimental paradigms which employ "conflict," such as the Geller-
Seitter procedure and the lick-suppression test. The effects of the 
benzodiazepines on other behaviors controlled by painful stimuli appear 
to be task-dependent. Thus, for example, the benzodiazepines can faci· 
litate two·way active avoidance acquisition, but fail to influence the 
acquisition of a one-way conditioned avoidance response. In addition, 
the benzodiazepines can affect locomotor activity, depending on the 
experimental parameters employed. The benzodiazepines appear to modify 
exploratory and locomotor activity predominantly in test situations 
which contain a high degree of novelty or fear-inducing stimuli. These 
behavioral effects of the benzodiazepines long have been viewed as 
reflective of their sedative and anxiolytic properties. 
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Neurotransmitter Role of GABA 
-----
One of the major inhibitory neurotransmitters in the central ner-
vous system (CNS) is gamma-aminobutyric acid (GABA) (Baxter, 1970; De 
Feudis, 1975; Johnston, 1978). Several indices have been considered and 
explored in attempts to demonstrate GABA-ergic neurons (Cooper ~ al., 
1978): 
The presence and concentration of GABA, itself. 
The presence and activity of the enzyme, glutamic acid decar-
boxylase (GAD), which catalyzes the conversion of glutamate to 
GABA. 
The presence and activity of the metabolizing enzyme, GABA-
transaminase (GABA-T). 
The high-affinity uptake of GABA. 
GABA receptor localization. 
Biochemical (Gabellec et al., 1980), immunohistochemical (Barber and 
Saito, 1975; Saito, 1976) and autoradiographic (Privat, 1976) studies of 
these indices have shown that GABA serves as a neurotransmitter through-
out the neuraxis (in the spinal cord, the cerebellum, the neostriatum, 
the neocortex, and many other brain regions). 
Physiology 
GABA functions as an inhibitory synaptic transmitter throughout 
the mammalian CNS. Although the net effect of GABA always is inhibi-
tory, this effect can be produced either by pre-synaptic depolarization, 
such as in the spinal cord substantia gelatinosa (Nishi et al., 1974; 
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Nicoll and Alger, 1979; HcGeer and HcGeer, 1981), or by post-synaptic 
hyperpolarization, such as commonly seen at higher levels in the CNS 
(MacLeod et al., 1980; Harciani et al., 1980; Hatthews et al., 1981; 
McGeer and HcGeer, 1981). Both the pre-synaptic depolarization and the 
post-synaptic hyperpolarization responses produced by GABA are brought 
about by an increase in the permeability of membranes to chloride ions. 
The response of post-synaptic neurons to GABA is determined by the 
interaction between two distinct membrane units, the GABA t:eceptor and 
the chloride ionophore. When GABA binds to its receptor, the chloride 
ion channel opens and allows a redistribution of chloride across the 
neuronal membranes along the electrochemical concentration gradient 
(Roberts, 1974; Costa and Guidotti, 1979; Olsen, 1982). An increase in 
permeability to chloride usually produces hyperpolarization due to an 
influx of chloride ions. The presynaptic depolarization, however, pro-
bably is due to an efflux of chloride from the nerve terminals, since 
these terminals contain relatively high concentrations of chloride 
intracellularly (Roberts and Hammerschlag, 1976). 
Pharmacology 
GABA is formed by the one-step decarboxylation of the alpha-amino 
acid, glutamate. This reaction is catalyzed by 1-glutamic acid decar-
boxylase (GAD), an enzyme with an absolut~ requirement for the cofactor 
PYridoxal phosphate (vitamin B-6). Synaptically released GABA is taken 
up by specific, sodium-dependent high-affinity reuptake systems into 
both presynaptic nerve terminals and surrounding glial cells. The major 
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route of metabolism is by transamination with alpha-ketoglutarate via 
the enzyme GABA-transaminase (GABA-T). The resultant metabolite, sue-
cinic semialdehyde, is rapidly oxidized to succinic acid by succinic 
semialdehyde dehydrogenase (SSA-DH). · For a review of GABA.metabolism, 
see Roberts and Hammerschlag (1976). 
Various pharmacological manipulations may be employed to alter 
GABA neurotransrnission. 
Enhancement of GABA-ergic 
activity 
Drugs can produce GABA-mimetic effects either by acting as ligands 
directly at the GABA receptor, or indirectly by increasing the avail-
ability or affinity of GABA for the receptor pos~-synaptically. 
Directly acting receptor agonists 
A number of conformationally restricted GABA analogues have been 
reported to be GABA receptor agonists (Johnston, 1978; Enna and Maggi, 
1979; Andrews and Johnston, 1979). Among the purported GABA agonists 
are muscimol (Johnston, 1978; Baraldi et al., 1979; Beaumont et al., 
1979; Worms et al., 1979), 4,5,6,7-tetrahydroisoxazolo-[5,4-c]-pyridine-
3-ol (THIP; Maurer, 1979; Arnt and Krogsgaard-Larsen, 1979), isoguvacine 
(Andrews and Johnston, 1979), kojic amine (Yarbrough et al., 1979) and 
SL76-002 (Bartholini et al., 1979). With the exception of SL76-002, 
none of these drugs crosses the blood-brain barrier in appreciable con-
centration (Johnston, 1978; Baraldi et al., 1979). The direct-agonist 
nature of SL76-002, moreover, recently has been questioned (Enna and 
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Maggi, 1979). For intracranial injections, muscimol has become the most 
widely used GABA receptor agonist due to its high affinity for the GABA 
receptor in vitro. For this reason, muscimol has been used extensively 
in the present series of experiments. 
Indirectly acting agents 
Indirectly acting GABA-mimetics include GABA reuptake inhibitors, 
releasing agents, inhibitors of degradation, and allosteric receptor 
ligands, such as the benzodiazepines. 
Inhibitors of GABA uptake: GABA is taken up both into nerve ter-
minals (Varon et al., · 1965) and glial elements (Henn and Hamberger, 
1971; Sellstrom and Sjoberg, 1975; Varon and Somjen, 1979) by specific 
high-affinity membrane transport systems. These two specific systems 
can be distinguished pharmacologically. There are drugs which are rela-
tively specific for nerve-terminal reuptake and others which are rela-
, 
tively specific for glial uptake of GABA. Among the relatively selec-
tive substrates for neuronal reuptake are 1-2,4-diaminobutyric acid, 
nipecotic acid, guvacine and cis-3-aminocyclohexane carboxylic acid 
(Iversen, 1978; Johnston, 1978; Wood et al., 1979). Glial reuptake is 
inhibited by such drugs as beta-alanine and beta-proline (Johnston, 
1978; Schousboe et al., 1979). These specificities, however, are only 
relative (De Feudis et al., 1979). 
The high-affinity uptake of labeled GABA can be used to identify 
GABA-ergic structures autoradiographically (Hokfelt and Ljungdahl, 1971; 
Iversen, 1978). These results must be interpreted cautiously, however, 
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because the correlation between the rate of GABA uptake, GAD activity 
and GABA levels tends to vary (Storm-Mathisen, 1975; Fonnum and Storm-
Mathisen, 1978). 
GABA releasing agents: At present, baclofen is the only known 
GABA releasing drug. A sterically-hindered structural GABA analogue, 
baclofen is thought to exert its muscle-relaxant activity through a 
release of intracellular GABA stores (Andrews and Johnston, 1979). 
Inhibitors of GABA degradation: Selective inhibition of the 
enzymes GABA-T or SSA-DH usually leads to increased levels of CNS GABA. 
This phenomenon is correlated with an anticonvulsant effect (Johnston, 
1978). Amino-oxyacetic acid is a potent inhibitor of GABA-T, and is 
used very commonly to increase brain GABA levels. A non-specific carbo-
nyl-trapping agent, amino-oxyacetic acid also inhibits GAD and many 
other transaminase enzymes (Johnston, 1978; Metcalf, 1979; Loscher, 
1980). 
Ethanolamine-a-sulfate is an excellent specific irreversible inhi-
bitor of GABA-T. This drug, however, does not penetrate the blood-brain 
barrier. Gamma-acetylenic GABA, gamma-vinyl-GABA and gabaculine act 
quite similarly to ethanolamine-a-sulfate, and, moreover, do cross the 
blood-brain barrier (Johnston, 1978; Loscher, 1980; Palfreyman et al., 
1981). 
Sodium di-g-propylacetate (sodium valproate) is a clinically 
effective anti-convulsant which acts more by inhibiting SSA-DH than by 
any action on GABA-T (Johnston, 1978; Palfreyman et al., 1981). All of 
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the aforementioned agents are effective in elevating central nervous 
system GABA levels. 
Allosteric ligands: The evidence that benzodiazepines act to 
facilitate GABA-ergic transmission by a modulatory effect on an allos-
teric post-synaptic site will be reviewed below. 
Inhibition of GABA-ergic 
activity 
Receptor antagonists 
Bicuculline: This convulsant drug which has been employed in the 
present work, is a specific competitive GABA-receptor antagonist (Mohler 
and Okada, 1977h; Johnston, 1978). Being insoluble in water and unsta-
bleat physiological pH (Olsen et al., 1975), (+)-bicuculline must be 
dissolved in an acidic vehicle for parenteral administration. Salt der-
ivatives which are water soluble, such as bicuculline hydrochloride and 
bicuculline methiodide, are more suitable for direct intracranial injec-
tion. When administered parenterally, however, these compounds, in con-
trast to (+)-bicuculline, do not cross the blood-brain barrier. 
Picrotoxin: This convulsant does not influence the binding of 
GABA to synaptic membranes. Instead, it interferes with the opening of 
the GABA-specific chloride ionophore, which is necessary for the post-
synaptic neuronal response (Johnston, 1978; Olsen et al., 1979). Thus, 
it seems that picrotoxin does not affect the interaction of GABA with 
GABA receptors, but rather the membrane molecules responsible for cont-
rolling chloride ion flux (Johnston, 1978). 
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Inhibitors of GABA synthesis 
3-Mercaptopropionic acid is a convulsant which reversibly inhibits 
GAD, while at the same time activating GABA-T (Johnston, 1978; Loscher, 
1979). This drug produces a rapid fall in brain GABA level. In addi-
tion, carbonyl-trapping agents, which act as inhibitors of the coenzyme, 
pyridoxal phosphate, will decrease the activity of GAD (Tapia, 1975). 
Anatomy 
Unlike the monoaminergic neuronal systems, which are organized 
into discrete long fiber pathways, GABA systems comprise predominantly 
short-fiber interneurons (Fonnum, 1978; Fonnum and Storm-Mathisen, 
1978). There are three principal exceptions to the "short axon rule" 
for GABA neurons: 1) the striatonigral, 2) the nigrothalamic, and 3) 
the pallidothalamic GABA projections (Fonnum and Storm-Mathisen, 1978). 
Since the primary focus of the present work is on midbrain structures, 
only the anatomy of GABA systems in the mesencephalon will be reviewed 
in detail. 
Substantia nigra 
The substantia nigra contains the highest concentration [ 4. 25 
pmole/gram wet tissue mass (Kanazawa et al., 1973; Balcom et al., 1975; 
Fonnum and Storm-Mathisen, 1978)] of GABA in the CNS. Within the sub-
stantia nigra there is a topographical variation in both GABA concentra-
tion and GAD activity, with the highest value for each occurring in the 
medial and central parts of the pars reticulata (Tappaz et al., 1977). 
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In the pars compacta, the levels are only one-half as great. In vitro 
autoradiographic studies have revealed a relatively high density of 
binding sites for the radiolabelled GABA-receptor agonist, 3 H-muscimol, 
over the substantia nigra zona reticulata, with only low densities seen 
over the zona compacta (Palacios et al, 1981a; 1981b). The origin of 
nigra! GABA and GAD has been investigated intensively over the past 
twenty years. It is accepted almost universally that the substantia 
nigra receives a number of GABA-ergic fibers from the corpus striatum 
(Hattori et al., 1973; Ribak et al., 1976; Fonnum and Storm-Mathis en 
1978). Destruction of the striatonigral pathway produces a greater than 
75% fall in nigra! GABA content and GAD activ.ity (Hattori 2E al., 1973; 
Minchin and Fonnum, 1979; Gale and Iadarola, 1980). In the cat, the 
striatonigral GABA projection has been found to have a distinct topo-
graphic organization (Fonnum et al., 1974). Briefly, fibers from the 
putamen and posterior caudate terminate mostly in the posterolateral 
pars reticulata, with fibers from the head of the caudate projecting 
mainly to the anteromedial region. The fibers from the lateral part of 
the caudate terminate intermediately. Recently, a similar pattern of 
distribution has been described in the rat (DiChiara et al., 1980). 
In addition to its extrinsic GABA-ergic input, evidence has been 
advanced for the existence of intrinsic GABA-ergic neurons in the pars 
reticulata which project to the pars. compacta (Cheramy et al., 1978; 
Cattabeni et al., 1979). Stimulation of the striatonigral tract enhances 
the firing rate of pars compacta neurons, presumably by inhibiting inhi-
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bitory (possibly GABA·ergic) cells in the pars reticulata. Thus, neu-
rons in the pars compacta are disinhibited (Grace et al., 1980). When 
iontophoretically applied directly into the pars compacta, GABA 
decreases neuronal firing. This evidence suggests that there is an 
inhibitory GABA-ergic interneuron in the pars reticulata, which termi-
nates on pars compacta neurons (DiChiara et al., 1979a). 
The substantia nigra also may be a source of GABA-ergic efferents 
to other brain regions (Anderson and Yoshida, 1977; Kilpatrick et al., 
1980). Using a combination of retrograde and orthograde tracing techni-
ques, Clavier et al. (1976) have found evidence for a nigrothalamic 
projection. Intranigral administration of the excitatory glutamate ana-
logue, kainic acid, causes a marked diminution of GAD activity in the 
ventromedial thalamus (DiChiara et al., 1978; DiChiara et al., 1979b; 
Straugham, 1979) and in the superior colliculus (Di Chiara et al., 
1979b). 
Ventral tegmental ~ 
Certain analogies have been drawn between the nigra- striatal 
dopamine system and the mesolimbic dopamine system (Fonnum and Storm-
Hathisen, 1978). Just as the corpus striatum receives a heavy dopamin-
ergic input from the substantia nigra (A-9), the nucleus accumbens, 
together with other limbic structures, receives a major dopaminergic 
input from the mesencephalic ventral tegmental area of Tsai (A-10; Hoare 
and Bloom, 1978). One might, therefore, expect a "limbomesencephalic" 
GABA projection which is analagous to the striatonigral pathway. 
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Indeed, a high level of GAD activity has been found in the ventral teg-
mental area (Fonnum et al., 1977), and iontophoretically applied GABA 
inhibits the activity of neurons in this area (Wolf et al., 1978). It 
appears, however, that GABA-ergic inhibition in the ventral tegmental 
area is mediated by local interneurons rather than a long fiber pathway, 
since interruption of descending fibers from the limbic forebrain does 
not alter tegmental GAD activity (Fonnum et al., 1977). 
Raphe nuclei 
It is now fairly well established that GABA serves as a neurotran-
smitter for inhibitory interneurons within the mesencephalic B-7 and B-8 
5-HT cell groups (Dahlstrom and Fuxe, 1964), which constitute the prin-
cipal origin of ascending 5-HT projections to the forebrain (Azmitia and 
Segal, 1978). These 5-HT systems are thought to regulate several phy-
siological and behavioral processes (see below). The median and dorsal 
raphe nuclei are rich sources of GAD activity (Hassari et al., 1976). 
Following intracerebroventricular administration of 3 H-GABA into the 
rat, autoradiography reveals labeled cell bodies and fibers in the dor-
sal raphe nucleus (Gamrani et al., 1979). Immunocytochemical localiza-
tion of GAD supports the presence of GABA-containing cell bodies, fibers 
and nerve terminals in the dorsal raphe nucleus (Nanopoulos et al., 
1980). Using a combination of horseradish peroxidase retrograde trans-
port, a GAD activity measure, and 3 H-GABA autoradiographic techniques, 
Belin and associates (1979) have provided evidence for a GABA system in 
the midbrain periaqueductal and pontine ventricular gray, including the 
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dorsal raphe nucleus (Pujol et al., 1981). In vitro autoradiographic 
studies have shown that 3 H-muscimol binding sites are present with a 
moderate density in the dorsal raphe nucleus (Palacios et al, 1981a; 
1981b). Gallager and Aghajanian (1976), furthermore, have shown that 
microiontophoretically applied GABA produces a picrotoxin-reversible 
inhibition of the spontaneous firing of dorsal raphe 5-HT cells, which 
is potentiated by both systemically and locally applied benzodiazepines 
(Gallager, 1978). 
Tegmental nuclei of Gudden 
Among the prominent brainstem nuclei, the dorsal tegmental nucleus 
of Gudden has been found to contain the highest level of GAD activity, 
with the ventral t~gmental nucleus of Gudden having a relatively low 
level (Massari et al., 1976). In addition, a moderately high density 
of 3 H-muscimol binding sites over the dorsal tegmental nuclei of Gudden 
has been reported (Palacios et al, 1981a; 1981b). Nauta (1958) 
included these tegmental nuclei within his limbic midbrain area because 
of their interconnections with the limbic forebrain. These areas, such 
as the hippocampus and dentate gyrus, also have been shown to possess 
high levels of GAD activity (Tappaz et al., 1976). 
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Neurotransmitter Role of Serotonin 
---
Serotonin (5 -hydroxytryptamine, 5 -HT), formed by the enzymatic 
5-hydroxylation of !-tryptophan and the subsequent decarboxylation of 
the resulting 5 -hydroxy-l-tryptophan, appears to function as a neuro-
transmitter in mammalian brain (Aghajanian and Wang, 1978; Fuller, 
1980). Largely confined to midbrain and hindbrain regions, distinct 
groups of 5 -HT containing perikarya first were described by Dahlstrom 
and Fuxe (1964), and labeled caudorostrally B-1 through B-9. 
Anatomy 
Histofluorescence (Dahlstrom and Fuxe, 1964), immunocytochemical 
(Steinbusch, 1981; Kulmala and Lorens, 1982), retrograde dye tracing 
(van der Kooy and Hattori, 1980b; van der Kooy and Steinbusch, 1980), 
and autoradiographic (Azmitia and Segal, 1978) techniques have been used 
to map out the projections of 5-HT neurons. The 5 -HT cell bodies 
largely coincide with the brainstem raphe nuclei (Taber et al., 1960). 
The more caudal B-1 through B-3 groups send axons principally to the 
spinal cord and lower medulla (Lorens, 1978; Loewy and McKellar, 1981). 
The B-4 through B-6 groups may provide both ascending and descending 
projections (Cooper et al., 1978; Lorens, 1978). The more rostral 5-HT 
cell groups (B-7 through B-9) are the source of extensive ascending pro-
jections to the forebrain. The B-7 cell group, which overlaps the dar-
sal raphe nucleus, projects primarily to the neostriatum, olfactory 
tubercle, amygdala, neocortex, hypothalamus and thalamus. The B-8 cell 
group, located predominantly in the caudal linear and median raphe nuc-
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lei, is the origin of 5-HT projections to such limbic structures as the 
septum and hippocampus, as well as to the cortex, hypothalamus and sub-
stantia nigra (Azmitia and Segal, 1978; Lorens, 1978; van de Kar and 
Lorens, 1979; Dray et al., 1976; 1978; van der Kooy and Hattori, 
1980a). 
Physiology 
Serotonin appears to function primarily as an inhibitory neuro-
transmitter (Cooper et al., 1978; Segal, 1981). Stimulation of the 5-HT 
containing median raphe nucleus inhibits the spontaneous activity of 
hippocampal neurons~ especially in the heavily innervated CA-l region 
(Segal, 1975). A similar effect is seen when 5-HT is applied iontopho-
retically. Electrical stimulation of the median raphe nucleus also 
inhibits the firing rates of medial septal neurons (Segal, 1976), wher-
eas stimulation of the dorsal raphe nucleus inhibits neurons in the 
amygdala (Wang and Aghajanian, 1977) and neostriatum (Miller et al., 
1975). Furthermore, perfusion in vitro with 5-HT produces a potassium-
dependent, non-chloride-dependent hyperpolarization of hippocampal CA-l 
cells (Segal, 1981). 
Microiontophoretically applied 5-HT has a powerful and direct 
inhibitory action on 5-HT neurons in the dorsal raphe nucleus (Aghaja-
nian and Wang, 1978). This is thought to be due to an action of 5-HT on 
" "· h d 1 autoreceptors 1.n t e orsa raphe nucleus. "Autoreceptors" may be 
defined as receptors which mediate the response of a neuron to its own 
transmitter. The autoreceptors are thought to reflect the presence of 
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s·HT collaterals. Raphe cells demonstrate a very characteristic slow, 
regular firing pattern (Aghajanian and Wang, 1978). All attempts to 
"drive" these neurons antidromically have resulted in an initial rapid 
burst of activity, followed by a period of post-stimulus depression. 
This is taken as physiological evidence for recurrent collateral inhibi· 
tion. Such autoregulatory mechanisms would allow raphe 5-HT cells to 
maintain a tonic level of activity within a narrow range (for review, 
see Aghajanian and Wang, 1978). 
Pharmacology 
Serotoninergic neurotransmission may be altered pharmacologically 
in several different ways. It is clearly possible to decrease the 
activity of serotonin neurons and to reduce the availability of 5·HT 
post-synaptically. It is, however, debatable as to whether it is possi· 
ble pharmacologically to enhance 5-HT neurotransmission other than by 
administering directly acting receptor agonists. Drugs which enhance 
the concentration of 5-HT in the synaptic cleft will lead to decreased 
firing of 5-HT neurons because 5-HT will act in an inhibitory manner at 
5-HT autoreceptors (Aghajanian and Wang, 1978). Thus, drugs, whose pre-
sumed mechanism of action (such as reuptake inhibition) depends on the 
release of 5-HT from axon terminals by neuronal discharge, will not lead 
to an effective enhancement of 5-HT neurotransmission, because the sub-
sequent increase in synaptic 5-HT concentration will result in negative 
feedback inhibition. By increasing the neurotransmitter concentration 
at other than autoreceptor sites, serotonin releasers and reuptake inhi-
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bitors would, nevertheless, produce an acute serotoninomimetic post-sy-
naptic response. 
Serotonin receptor agonists 
Receptor agonists include quipazine, bufotenin, lysergic acid die-
thylamide, N,N-dimethyl-5-methoxytryptamine and pipamperone. These 
drugs bind to the 5-HT receptor and produce a serotonin-mimetic effect. 
Quipazine has been reported to produce behavioral effects characteristic 
of a 5-HT receptor agonist (Green et al., 1976; Jacoby et al., 1976). 
It would appear, however, that the apparent agonist effects of quipazine 
may, in fact, be due to an antagonism of 5-HT autoreceptors (Martin and 
Sanders-Bush, 1982). 
··Among the indirectly acting compounds are the 5-HT reuptake inhi-
bitors, releasers, precursors and inhibitors of degradation. 
Inhibitors of 5-HT reuptake 
The tertiary-amine tricyclic antidepressants (for example, imipra-
mine) inhibit 5-HT reuptake at the presynaptic nerve terminal. These 
compounds, however, also inhibit norepinephrine reuptake to a certain 
extent (Baldessarini, 1980). Fluoxetine, zimelidine and paroxetine are 
some of the more selective 5-HT reuptake inhibitors. Zimelidine, how-
ever, is metabolized to norzimelidine, which inhibits noradrenaline 
reuptake (Fuller, 1980). 
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5-HT releasing agents 
-
The drugs ,e-chloroamphetamine and fenfluramine, in addition to 
inhibiting serotonin nerve-terminal reuptake, release serotonin (as well 
as norepinephrine) from vescicular stores (Trulson and Jacobs, 1976; 
Fuller, 1978). These two compounds also have been reported to produce 
long-term reductions in CNS serotonin concentrations, presumably by 
inhibiting tryptophan hydroxylase (Sanders-Bush and Steranka, 1978; 
Fuller, 1980). 
5-HT precursors 
The administration of the 5-HT precursors, 1-tryptophan and 
5-hydroxy-1-tryptophan, leads to elevations in brain 5-HT level. Unfor-
tunately, both of these compounds are somewhat non-specifi-c. The essen-
tial amino acid, 1-tryptophan, is taken up by virtually all cells and 
incorporated into their protein metabolism. 5-Hydroxy- 1-tryptophan is 
taken up by catecholaminerg~c neurons, in which it can be decarboxylated 
to 5-HT and released ectopically (Yunger and Harvey, 1976). 
Inhibitors of 5-HT degradation 
The only known inhibitors of 5-HT catabolism are the monoamine 
oxidase inhibitors. None of these drugs, however, is selective for 5-HT 
degradation since monoamine oxidase also is a major enzyme in the meta-
holism of the catecholamines (Baldessarini, 1980). 
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S·HT antagonists 
-
The drugs which decrease 5-HT neurotransmission are the 5-HT 
receptor antagonists, inhibitors of serotonin synthesis, and depletors 
of serotonin stores. Some of the recently identified 5-HT receptor 
antagonists are cyproheptadine, methysergide, metergoline, methiothepin, 
cinanserin and mianserin (Aghajanian and Wang, 1978; Fuller, 1980). 
These drugs, however, possess varying degrees of dopamine agonist activ-
ity. In addition, cyproheptadine is a well known histamine antagonist. 
Furthermore, it is uncertain whether these agents are effective antago-
nists at all 5-HT receptors (see Aghajanian and Wang, 1978; Martin and 
Sanders-Bush, 1982). 
Inhibitors of 5-HT synthesis 
The precursor enzyme in the synthesis of serotonin, tryptophan 
5·hydroxylase is inhibited by £-chlorophenylalanine. The resultant 
enzymatic inhibition is irreversible and thus leads to a prolonged (up 
to 2 weeks) decrease in tryptophan hydroxylase activity. £-Chlorophe-
nylalanine, however, also inhibits both tyrosine and phenylalanine 
hydroxylase. As mentioned above, £-chloroamphetamine and fenfluramine 
also produce long-lasting (several weeks) reductions in CNS 5-HT concen-
trations. 
i:[I neurotoxins 
The neurotoxins, 5, 6- and 5, 7 -dihydroxytryptamine, when injected 
intracerebrally, either locally or into the ventricles, destroy 5 -HT 
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containing perikarya and processes with a high degree of specificity 
(Bjorklund et al., 1973; Lorens, 1978). A secondary-amine tricyclic 
antidepressant, such as desmethylimipramine, however, must be used as a 
pretreatment in order to prevent the uptake of the dihydroxytryptamines 
into noradrenergic neurons. 5,7-Dihydroxy- tryptamine has several advan-
tages over 5,6-dihydroxytryptamine (see Lorens, 1978), and thus was used 
in the present study. 
Serotonin and Behavior 
CNS 5-HT systems have been postulated as playing important roles 
in several psychological and physiological processes, including tempera-
ture regulation (Hyers, 1975; 1981; Hyers and Sharpe, 1968; Myers and 
Waller, 1975); modulation of luteinizing hormone, prolactin and renin 
release (van de Kar et al., 1980; 1981; Koenig et al., 1980); the res-
ponse to painful stimuli and morphine analgesia (Hessing and Lytle, 
1977) and, the control of mating behavior (Karc2mar, 1980). It is out-
side the scope of this dissertation to review all of these proposed 
functions. Thus we shall focus our comments on those behaviors which 
are modified by the benzodiazepines, possibly via an effect on the 
activity of raphe 5-HT neurons. 
Punished behavior 
The existence of a 5-HT "punishment" system has been postulated 
(Stein et al., 1973; 1975; Haefely, 1978). If such a system exists, one 
would expect pharmacological manipulation of CNS 5 -HT systems to have 
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appreciable effects of punished behaviors. The putative 5-HT receptor 
antagonists, methysergide, cinanserin and cyproheptadine, have been 
reported to produce anti-conflict effects (Cook and Sepinwall, 1975b; 
Sepinwall and Cook, 1978; 1980). Serotonin synthesis inhibitors, such 
as E-chlorophenylalanine, moreover, have similar effects (Koe, 1979; 
Sepinwall and Cook, 1978; 1980). Destruction of 5-HT neurons with 5,6-
and 5, 7-dihydroxytryptamine also can release punished behavior as mea-
sured in conflict tests, regardless of whether these agents are adminis-
tered intracerebroventricularly (Sepinwall and Cook, 1978) or injected 
directly into the ascending 5-HT pathways in the ventromedial mesence-
phalic tegmentum (Tye et al., 1977; 1979). 
Locomotor activity 
The effects of 5-HT depletion on locomotor activity are dependent 
upon the type of surgical and pharmacqlogical intervention, as well as 
upon the behavioral paradigm employed (Lorens, 1978). Electrolytic 
lesions of the median but not of the dorsal raphe nucleus produce 
hyperactivity in both a familiar (home cage; Kostowski et al, 1968) and 
novel (open field; Srebro and Lorens, 1975; Hole et al., 1976) environ-
ment. In the open field, 5,7-dihydroxytrypt- amine lesions, in contrast 
to electrolytic lesions, do not alter activity level. £-Chlorophenyla-
lanine also fails to affect open field activity (Kohler and Lorens, 
1978), while .E-chloroamphetamine produces a decrease in activity (for 
review, see Lor ens, 19 78). On the other hand, increases in home cage 
activity have been obtained after systemic injection of the tryptophan 
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hydroxylase inhibitors, £-chlorophenylalanine and £-chloroamphetamine, 
as well as following 5,7-dihydroxytryptamine lesions (Mackenzie et al, 
1978). Recently, Williams and Azmitia (1981) microinjected different 
doses (1.0 - 10 ~g) of 5,7-dihydroxytryptamine into the fornix-fimbria 
which contains 5-HT fibers afferent to the hippocamus. These injections 
produced a dose-related increase in nocturnal locomotor activity (as 
measured in photocell chambers) during the seven consecutive nights of 
.testing. A reduction of 3 H-5-HT uptake was found in the dorsal hippo-
campus and was related to the dose of 5, 7 -dihydroxytrypta- mine. The 
degree of dorsal hippocampal 3 H-5-HT uptake was negatively correlated 
with the mean nocturnal activity for the seven nights of testing. These 
authors interpreted their results to imply that the increase in noctur-
nal locomotor activity produced by a generalized depletion of 5-HT in 
the brain may be due to disruption of hippocampal 5 -HT terminals sup-
plied by the fornix-fimbria. 
It is of interest to note that bilateral electrolytic lesions in 
the ventral and dorsal tegmental nuclei of Gudden which lie in close 
proximity to the median and dorsal raphe nuclei, respectively, can pro-
duce increases in open field locomotor activity similar to those seen 
after electrolytic raphe lesions (Lorens et al., 1975; Lorens, 1978). 
This, as well as the data alluded to above, suggests the possibility 
that the effects of electrolytic raphe lesions on locomotor activity may 
not be due solely to the destruction of 5-HT containing cells. The 
behavioral consequences of raphe and Gudden lesions are not, however, 
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identical. While bilateral destruction of the tegmental nuclei of Gud-
den enhances the acquisition of a two-way (shuttlebox) avoidance task, 
only combined, not selective, electrolytic dorsal and median raphe 
nucleus lesions produce a similar effect (Lorens et al., 1975; Lorens, 
1978). 
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GABA-Benzodiazepine Interactions 
~ 
In light of the potent central nervous system effects of the ben-
zodiazepines, efforts have been made to localize CNS benzodiazepine 
receptors. Recently, high -affinity, saturable, stereospecific binding 
sites for benzodiazepines have been found both in vivo (Williamson et 
al., 1978; Chang and Snyder, 1978), and in vitro (Squires and 
Braestrup, 1977; Hohler and Okada, 1977 a; Tallman et al.; 1980). The 
existence of such receptors for benzodiazepines has prompted a search 
for endogenous ligands. Several substances, including the purines, ino-
sine and hypoxanthine; the cofactor, nicotinamide; a beta-carboline; 
and a small peptide, GABA-modulin, have been proposed as possible 
endogenous ligands. To date the evidence is not compelling for any one 
of these substances (for a review, see Paul et al., 1980). 
Studies of the biochemical regulation of the benzodiazepine recep-
tor have revealed that GABA and GABA-mimetics, such as muscimol, 
increase, while GABA-receptor antagonists, such as bicuculline, decrease 
the affinity of benzodiazepines for their receptors (Tallman et al., 
1978; 1980). Moreover, permeable halide ions such as chloride and iod-
ide, but not large anions such as citrate or sulfate, increase the 
affinity of radiolabeled benzodiazepines for their receptor (Costa et 
al., 1979). These findings suggest that the benzodiazepine receptor is 
coupled. to both a GABA receptor and a chloride ionophore. These bio-
chemical data are supported by electrophysiological observations sug-
gesting an interaction of benzodiazepines with both a GABA receptor and 
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a chloride ionophore (MacDonald and Barker, 1979; Costa et al., 1979; 
1981). Although the morphological correlation between the distributions 
of putative GABA and putative benzodiazepine binding sites in vitro is 
----
not perfect, there is a significant degree of overlap (see Young and 
Kuhar, 1979, 1980; Palacios et al, 1981a; 1981b). These observations 
support the hypothesis of a receptor complex in the mammalian central 
nervous system which consists of a functionally coupled benzodiazepine 
receptor, GABA receptor, and chloride ionophore (Costa and Guidotti, 
1979; Tallman et al., 1980; Paul et al., 1981a; Olsen, 1982). 
The benzodiazepine binding site has a truly neuromodulatory role. 
The interaction of this site with its ligand produces an increase in the 
affinity and/or number of GABA receptors. The benzodiazepines depend on 
the synaptic release of GABA in order to produce their physiological 
effects. In the absence of GABA, the binding of a benzodiazepine to its 
receptor does not produce any changes in the post-synaptic membrane 
potential. It now appears that the benzodiazepines may exert many, if 
not all, of their pharmacological effects (including their anxiolytic, 
soporific, anti-convulsant, and muscle relaxant properties) by affecting 
this system (Haefely et al., 1975; Costa and Guidotti, 1979; Krogs-
gaard-Larsen and Arnt, 1980; Paul et al., 1981; Paul and Skolnick, 
1981; Olsen, 1982). 
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Serotonin-Benzodiazepine Interactions 
Benzodiazepines exert several effects on 5-HT metabolism. 
Firstly, 5-HT synthesis and turnover rates are decreased. Secondly, 
removal of the 5-HT metabolite 5-hydroxy-3-indoleacetic acid (5-HIAA) 
from the brain is inhibited. Steady-state levels of 5-HT may or may not 
be increased (Chase et al., 1970; Koe, 1979). 
A slower rate of turnover most likely represents a decrease in 
5-HT release due to a reduction in the activity of serotonergic neurons. 
Benzodiazepines reduce accumulation of 3 H-5-HT and 3 H-5-HIAA after 
intravenous 3 H-tryptophan (Dominic et al., 1975). They also retard the 
disappearance of radiolabe1ed 5-HT following intracisternal injection of 
14 C-5HT. Interference with transport of 5-HIAA from the brain has been 
inferred from the slower disappearance of labeled 5-HIAA from the brain 
following intracisternal injection of either 14C-5-HT or 14C-5-HIAA 
(Chase et al., 1970). Furthermore, tolerance does not develop to the 
reduction in 5-HT turnover produced by repeated daily injections of oxa-
zepam (Wise et al., 1972; Stein et al., 1975). The ability of the ben-
zodiazepines to decrease 5 -HT turnover and to decrease serotonergic 
activity in the brain may underlie several of their behavioral effects. 
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Midbrain Benzodiazepine-GABA-Serotonin Interactions 
As mentioned above, there is a good deal of evidence to support 
the role of GABA as a neurotransmitter within the mesencephalic dorsal 
and median raphe nuclei (Gamrani et al., 1979; Nanopoulos ~ al., 
1980; Belin et al., 1979;). Using an immunocytochemical double-label-
ing technique, Pujol and coworkers (1981) claim to have found neurons in 
the dorsal raphe nucleus which contain both GAD and 5-HT. Close exami-
nation of their data, however, reveals that the two stains are not uni-
formly distributed within the double-labeled cells. Their appearance 
and pattern of distribution, moreover, suggests the presence of GAD-po-
sitive terminals on 5-HT perikarya, rather than the coexistence of GAD 
and 5-HT within the same cell bodies. 
Young and Kuhar (1980) recently have demonstrated moderate to 
dense benzodiazepine binding in the periaqueductal gray, the dorsal 
raphe nucleus, the dorsal and ventral tegmental nuclei of Gudden, and 
the more caudally located raphe pontis and raphe magnus nuclei. We have 
found, in addition, moderate benzodiazepine receptor labelling in the 
region of the median raphe nucleus (Sainati et al., 1982). 
When microiontophoretically applied to spontaneously firing dorsal 
raphe 5-HT cells in the rat, GABA produces a picrotoxin-reversible inhi-
bition of spontaneous firing, which is potentiated by both systemically 
and locally applied benzodiazepines (Gallager and Aghajanian, 1976; Gal-
lager, 1978). In addition, systemic diazepam and chlordiazepoxide have 
been found to produce a dose-dependent suppression of raphe unit activ-
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itY in freely-moving cats (Preussler et al., 1981). Moreover, Przew-
locka and coworkers (1979) have reported that injection of muscimol into 
the dorsal raphe nucleus significantly reduces 5-HT and 5-HIAA levels in 
the hypothalamus, but not in the neostriatum. Forchetti and Meek 
(1981), furthermore, recently have examined the effects of GABA agonists 
and antagonists, locally applied to the median raphe nucleus, on hippo-
campal 5-HT and 5-HIAA concentrations in probenecid pretreated rats. 
They found that muscimol ( 100 ng) decreased 5 -HT turnover 90 minutes 
post-injection, whereas picrotoxin (2.0 ~g) and bicuculline methiodide 
(2.0 ~g) produced opposite results. The hippocampal content of 5-HT was 
not affected. Parenteral diazepam ( 5.0 mg/kg, intraperitoneally) 
blocked the effects of the GABA antagonists and potentiated the action 
of muscimol. These results provide evidence for a tonic inhibition by 
GABA neurons of the firing rate of 5 -HT perikarya in the median raphe 
nucleus. 
If serotonin and GABA constitute a bipole system, and as inactiva-
tion or destruction of CNS 5-HT systems produces certain specific beha-
vioral changes (see above), then GABA-ergic inhibition of these systems 
should produce similar changes. Intracisternal administration of the 
GABA-transaminase inhibitor, ethanolamine-a-sulfate, has been reported 
to produce an increase in exploratory locomotor activity (File, 1977). 
In addition, injection of the GABA analogue, muscimol, directly into the 
dorsal raphe nuclei of ether-anesthetized rats, has been observed to 
greatly increase their locomotor activity (PrzewZocka et al., 1979). 
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These effects were antagonized by both local and systemic injections of 
bicuculline and picrotoxin. 
Experimental Plan 
The literature reviewed above suggest that some of the clinical 
and behavioral effects of the benzodiazepines may be due to their 
enhancement of GABA-ergic neurotransmission in the midbrain raphe nuc-
lei. The data suggest, furthermore, that benzodiazepine-enhanced GABA-
ergic inhibition of serotonergic neurons may produce striking changes in 
appetitive behavior, avoidance behavior, punished behavior and locomotor 
activity. We, therefore, undertook a series of experiments designed to 
investigate the extent to which GABA-ergic modulation of midbrain raphe 
serotonergic neurons influences locomotor activity in the rat. 
First we replicated the findings of Przewlocka and associates 
(1979) that the acute microinjection of muscimol (100 ng) into the dor-
sal raphe nucleus produces hyperactivity. Secondly, we found that the 
acute microinjection of muscimol (100 ng) into the median raphe nucleus 
produced increases in activity which were 4 times greater than those 
seen after similar injections into the dorsal raphe nucleus. A dose-
response analysis using animals with chronically-indwelling cannulae, 
and a complex Latin square design, showed that the median raphe nucleus 
indeed was more sensitive to the effects of muscimol. Thus, subsequent 
experiments utilized only cannulae implanted chronically in the median 
raphe nucleus. 
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To determine whether the hyperkinesis produced by the intra-raphe 
injection of muscimol was due to activation of GABA receptors, we 
attempted to potentiate the effects of muscimol by administering intra-
peritoneally the benzodiazepine, chlordiazepoxide, and to block the 
effect with the GABA antagonist, bicuculline. 
The success of these experiments prompted us to determine whether 
the effects of the peripherally administered bicuculline and chlordiaze-
poxide were due to their binding to the same neuronal membranes as the 
intra-raphe muscimol. We thus conducted the following series of experi-
ments. First, intra-raphe dose-response analyses for the water soluble 
benzodiazepines, chlordiazepoxide, flurazepam and midazolam, were per-
formed. A similar study was carried out using bicuculline methiodide. 
Subsequently, animals received sub-effective doses of flurazepam or 
midazolam, followed by a sub-effective dose of muscimol, into the median 
raphe nucleus. Finally, animals received a combination of bicuculline 
methiodide and muscimol into the median raphe nucleus to determine 
whether the former drug would block the effects of the latter. The 
results from these experiments supported the view that the intra-raphe 
injection of muscimol produces hyperkinesis via an activation of local 
GABA receptors. 
Since destruction of the ventral tegmental nuclei of Gudden pro-
duces hyperactivity, and since these nuclei have been reported to con-
tain a high density of benzodiazepine receptors, we investigated the 
effect such lesions on the intra-raphe muscimol dose-response relation-
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shiP· To ascertain the role of ascending 5-HT systems in the mediation 
of the hyperkinetic effect of intra-raphe muscimol, we examined the mus· 
cimol dose-response relationship following 5, 7 -dihydroxytryptamine 
induced degeneration of these projections. 
The results obtained from these experiments, overall, strongly 
suggest that the activation of midbrain GABA receptors produces a hyper-
kinetic response in rats which depends on the integrity of an ascending 
serotonin system for its expression. 
CHAPTER II 
MATERIALS AND METHODS 
Animals 
The experimental subjects were male Sprague-Dawley rats (King Ani-
mal Farms, Orange, WI), 90 - 120 days old and weighing 310 - 375 grams 
at the time of surgery. The animals were housed individually in a temp-
erature (22 +/- l°C), humidity (40 - 52%), and illumination (12 hour 
light-dark cycle) controlled room. Food and water were available ad 
libitum in the home cage. 
Surgery 
A Kopf stereotaxic instrument was used. The incisor bar was set 
3.2 mm above the interaural plane. At the time of surgery, each animal 
, 
received 50 mg/kg ampicillin (Omnipen-N, Wyeth) and 0.4 mg/kg atropine 
sulfate (Lilly), intramuscularly, and chloramphenicol (Chloromycetin, 1% 
ophthalmic ointment; Parke-Davis) topically around the wound. For the 
acute intra-raphe microinjections, ether (Malinckrodt) was employed as 
an anesthetic, and the wound margins were infiltrated with 0.1 ml of 
lidocaine hydrochloride (Xylocaine; Astra, Worcester, MA) in order to 
minimize post-operative pain. For other surgical procedures intraperi-
toneal pentobarbital sodium (SO mg/kg; Butler, Columbus, OH) was used as 
an anesthetic. All wounds were closed with autoclips (Clay Adams). 
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Acute Intra-Raphe Injections 
Muscimol (100 ng in 0. 5 )ll of vehicle) or saline (0. 5 J.ll) was 
administered via a 5.0 ul Hamilton syringe with a 30-gauge needle (0.35 
mm o.d.) oriented mid-sagittally at an angle of 47° caudal to the verti-
cal plane. The solution was delivered slowly (in about 60 seconds). The 
needle was left in situ for 2 min following completion of the injec-
tion. Coordinates for the dorsal raphe placement were 6.2 mm caudal and 
9.6 mm ventral to the skull surface 1.0 mm rostral to lambda (L + 1). 
Coordinates for the median raphe placement were 8.1 mm caudal and 12.1 
mm ventral to L + 1. 
Chronic Intra-Raphe Cannula Placement 
A guide cannula (0.46 mm o.d. and 0.25 mm i.d.; Plastic Products 
Co., Roanoke, VA) was implanted in either the dorsal or the median raphe 
nucleus. A stylet (0.23 mm dia) then was inserted such that its tip was 
flush with that of the guide cannula. This assembly then was cemented 
onto stainless steel anchoring screws embedded in the skull. The coor-
dinates were the same as mentioned above. 
Electrolytic Lesions 
A 0.25 mm diameter stainless steel wire insulated with Expoylite 
except at the cross section of its tip was used as the lesion electrode. 
This electrode was connected to the positive pole of a Grass model 
DCLM-5A direct current lesion maker (Grass Medical Instruments Co., 
Quincy, MA). An alligator clip attached to the wound margin served as 
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the ground. Lesions were produced bilaterally in the ventral tegmental 
nuclei of Gudden (VTG) by passing 2.0 milliamperes direct current for 2 
seconds via the anode. The anode was inserted stereotactically at an 
angle 47° caudal to the vertical plane. The coordinates used were 0.5 
mm lateral to the midsagittal suture, and 7.5 mm caudal and 11.7 mm ven-
tral to the skull surface at L + 1. 
Neurotoxic Lesions 
The specific serotonin neurotoxin, 5,7-dihydroxy- tryptamine crea-
tinine sulfate (5,7-DHT; Sigma Chemical Co., St. Louis, MO), was dis-
solved in 0. 2% ascorbate in 0. 9% saline, and was injected bilaterally 
either into the lateral cerebral ventricles (75 ~g free base in 5.0 pl 
vehicle), or into the ventromedial mesencephalic tegmentum (4.0 pg base 
in 2.0 pl) at a rate of 0.5 pl/minute. The coordinates used were 0.5 mm 
rostral to bregma, 1.2 mm lateral to the midline, and 5.5 mm ventral to 
the skull surface for the lateral ventricle injections; and, an angle of 
47° caudal to the vertical plane, 5.5 mm caudal to lambda, 0.6 mm 
lateral to the midline, and 11.0 mm ventral to the reading at lambda for 
the mesencephalic tegmentum injections. These subjects all received 
desmethylimipramine hydrochloride (Merrell, Cincinnati, OH), 20 mg/kg 
intraperitoneally, 30 - 45 minutes prior to surgery. Because desmethy-
limipramine potentiates the anesthetic effects of pentobarbital, the 
dose of the anesthetic for these animals was 35 mg/kg. 
Drugs 
Intraperitoneal Administration 
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Chlordiazepoxide hydrochloride (Roche, Nutley, NJ) was dissolved 
in 0.9% saline to final concentrations (as the base) of 3.1, 6.3, 12.5, 
25.0 and 50.0 umole/ml (0.9, 1.9, 3.8, 7.5 and 15.0 mg/ml). 
(+)-Bicuculline (Sigma) was dissolved in acidified vehicle (pH = 5.5 -
6.0) to final concentrations of 0.19, 0.38, 0.75, 1.50 and 3.00 umole/ml 
(0.04, 0.07, 0.14, 0.27, 0.55 and 1.10 mg/ml). 
Intracranial Administration 
All drugs injected intracranially were dissolved in 0.9% saline. 
Muscimol (Sigma) was prepared in concentrations of 0.22, 0.44, 0.88, 
1.75 and 3.50 nmole/ 0.5 pl (25, 50, 100, 200 and 400 ng/ 0.5 p.l). 
Bicuculline methiodide (Pierce Chemical Co., Rockford, IL) was prepared 
in concentrations (as the base) of 0. 22, 0. 44 and 0. 88 nmole/ 0. 5 )ll 
(81, 161 and 323 ng/ 0.5 pl). Chlordiazepoxide hydrochloride (Roche), 
flurazepam dihydrochloride (Roche), and midazolam maleate (Roche) were 
prepared in concentrations of 0.11, 0.22, 0.44, 0.88 and 1.75 nmole/ 0.5 
ul. These concentrations, expressed in terms of mass (of the base), 
are: chlordiazepoxide - 44, 88, 175, 350 and 700 ng; flurazepam - 43, 
85, 170, 340 and 680 ng; and midazolam - 36, 71, 143, 286 and 571 rig. 
Biochemical Analysis 
The animals were killed by decapitation and their brains quickly 
removed and dissected on a glass plate over dry ice as described by Lor-
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ens and Guldberg (1974). The hippocampi and striata were wrapped in 
aluminum foil, flash frozen in liquid nitrogen, and stored in a -70°C 
freezer for no more than 3 weeks prior to assay. The brainstems were 
placed in phosphate-buffered formalin and fixed for at least 2 weeks 
prior to sectioning. 
Serotonin (5-HT) and 5-hydroxy-3-indoleacetic acid (5-HIAA) levels 
were determined by high-performance liquid chromatography (HPLC; Hef-
ford, 1981). Each tissue sample was sonicated for 20 sec in 500 ul of 
0.1 !:! perchloric acid which contained 1. 0 m~ sodium EDTA, 0. 3 mH 
thioglyoxylic acid, and 50 ~g of the internal standard, N-me-
thyl-5-hydroxytryptamine (NHSHT). The homogenate wa:s centrifuged at 
15,000 x ~ for 10 min, then microfiltered by centrifugation using mil-
lipore tubes. The filtrate was drawn into a six port rotary valve 
(Rheodyne Hodel No. 7125) and injected into an HPLC system (BioAnalyti-
cal Systems, Inc., West Lafayette, IN) utilizing a reverse phase column 
(lOJ.lm ~-Bondapak C-18, Waters Associates, Milford, MA) and a Waters 
Model No. M-45 pump. The mobile phase consisted of 0.15 M monochloroa-
cetic acid, 10 m~ octanylsulfonic acid and 1.0 mM EDTA. The flow rate 
was 1.5 ml/min. Electrochemical detection was accomplished with an LC-4 
amperometer (BioAnalytical Systems). Retention times were: 5-HIAA -
24.8 min, 5-HT - 29.8 min, and NM5HT - 32.3 min. 
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Histology 
Those animals not requiring biochemical determinations of 5-HT and 
5-HIAA levels were perfused transcardially with 100 ml of saline fol-
lowed by 100 ml of phosphate-buffered formalin. Their brains then were 
removed and post-fixed for at least one week prior to sectioning. After 
the tissue was well fixed, it was transferred to a solution containing 
5% sucrpse in 0.1 M phosphate buffer for 24 - 48 hours. The tissue 
then was frozen with dry ice and cut on a sliding microtome. Every 
fourth section (SO pm) was retained, mounted on a gelatin coated slide 
and stained using the cresylecht violet procedure (Powers and Clark, 
1955) . 
Apparatus 
Activity level was measured in enclosed cylindrical photocell 
chambers (46 em dia x 42 em high; Model No. PAC-001, Lehigh Valley Elec-
tronics, Inc., Beltsville, MD) with wire mesh floors. The interiors of 
the walls and covers of these chambers were painted flat black. Inter-
ruption by the animal of any one of six photocell beams located at the 
base of the chamber activated an electromechanical counter. 
Statistical Analysis 
The data from Experiment II were analyzed using a complex Latin 
square design (Bruning and Kintz, 1977, pp. 92-106). Data from Experi-
ments III and IV were analyzed using an analysis of variance (ANOVA) 
with a repeated measures -two factors design (ibid, pp. 48-54). The 
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data from the biochemical and the remaining behavioral experiments were 
analyzed by an ANOVA, two-factor mixed design with repeated measures on 
one factor (ibid, pp. 55-61); and, a three-factor mixed design with 
repeated measures on two factors (Kirk, 1968; Bruning and Kintz, 1977, 
pp. 73-84). Individual between-group comparisons were performed, when 
merited, by Newman-Keuls' multiple range test (Newman, 1939; Keuls, 
1952; Bruning and Kintz, 1977, pp. 119-122), or by an F-test. for simple 
effects (ibid, pp. 140-142). For within group comparisons, a Newman-
Keuls test for related measures (Keuls, 1952; Bruning and Kintz, 1977, 
pp. 137-138) was used. Statistical analyses were performed on a Hew-
lett-Packard HP-85 minicomputer with a No. 90053 statistical program 
package, as well as with Nos. 300-0027, 300-0029, 300-0035 and 300-0043 
ANOVA programs (Hewlitt-Packard Corp., Corvallis, OR). 
CHAPTER III 
RESULTS 
Experiment I 
ACUTE INTRA·MIDBRAIN MICROINJECTIONS OF MUSCIMOL 
It has been reported (Przewlocka et al., 1979) that acute injec-
tions of muscimol (50 and 100 ng) into the dorsal raphe (DR) nucleus of 
rats produce elevations in locomotor activity. In our first experiment, 
we attempted to replicate these findings. In addition, the effects of 
muscimol injections into the DR were compared to those following injec-
tions into the median raphe nucleus (MR). 
Procedure 
Rats were anesthetized with ether and injected with muscimol (100 
ng in 0.5 ~1 of saline) or saline (0.5 pl) into either the DR (n = 7) or 
the MR (n = 7) as described in the Materials and Methods section (Chap-
ter II). Four additional animals served as sham-operated controls. 
These animals were treated in the same manner as the injected rats, 
except that a needle was not lowered into their brains. Fifteen minutes 
post-injection, the rats, fully awake, were placed in the photocell 
chambers, and their activity counts recorded every 15 minutes for 90 
minutes. 
58 
59 
Results 
His~ological analysis 
Of the 7 animals which received muscimol injections into the MR, 
one was eliminated from the study prior to analysis of the behavioral 
data because the needle tract terminated 1.5 mm laterally in the mesen-
cephalic reticular formation. Of the remaining animals, the needle tips 
in 4 terminated in the rostral extent of the B-8 5-HT cell group 
(Dahlstrom and Fuxe, 1964; Steinbusch, 1981; Kulmala and Lorens, 1982) 
just dorsal to the rostral one-third of the interpeduncular nucleus. 
The needle tips in the other 2 rats were localized in the MR at the 
level of the ventral tegmental nucleus of Gudden (Figure 3). The needle 
tips of the 3 animals which received vehicle injections into the MR were 
similarly placed at the level of the ventral tegmental nucleus of Gud-
den. 
Of the 7 animals which received muscimol injections into the DR, 
one was rejected from further analysis because the needle tip was local-
ized within the lumen of the cerebral aqueduct. In the remaining ani-
mals, the needle tips terminated in the rostral DR at the level of the 
third and fourth cranial nerve nuclei (Figure 4). The animals which 
received vehicle injections into the DR had similar needle placements. 
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Figure 3: Photomicrograph of median raphe (MR) needle tip. 
Cresylecht violet stained coronal section (50 J.lm) through 
the caudal midbrain of a MR-muscimol injected rat from 
Experiment I. The needle tip (black arrow) appears as a 
small cavity rimmed by a glial scar, and, in this animal, 
terminates in the caudal portion of the B-8 5-HT cell group 
at the level of the VTG. Bar represents 1 mm. 
Abbreviations: Aq = cerebral aqueduct of Sylvius; IPN = 
interpeduncular nucleus; ML =median lemniscus; MLF =medial 
longitudinal fasciculus; VTG = ventral tegmental nucleus of 
Gudden. 
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Figure 4: Photomicrograph of dorsal raphe (DR) needle tip. 
Nissl stained coronal section (50 pm) through the midbrain 
of a DR-muscimol injected rat from Experiment I. The needle 
tip (black arrow) appears as a small cavity rimmed by a 
glial reaction, and, in this animal, terminates in the 
rostral part of the B-7 5-HT cell group at the level of en 
IV. Bar represents 1 nun. Abbreviations: Aq = cerebral 
aqueduct of Sylvius; en IV= trochlear nucleus. 
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Activity level 
An ANOVA of the number of counts per 15 minutes failed to demons-
trate any significant differences between the 4 sham-operated, the 3 
MR-vehicle injected, and the 3 DR-vehicle injected animals. These 
groups, therefore, were combined into a single control group. Subse-
quently an ANOVA revealed significant treatment [F(2,20)=23.3, p<O.OOl], 
time [F(14,140)=13.4, p<O.OOl], and interaction [F(14,140)=7.6, p<O.OOl] 
effects between the control and muscimol injected groups. The cumula-
tive activity scores per 15 minutes for each group are shown in Figure ~ 
Between-group comparisons of the total 90 minute activity scores 
showed that both the MR- and DR-muscimol injected groups were signifi-
cantly more active than the. control group. The MR-muscimol injected 
group, furthermore, was significantly more active than the DR-muscimol 
injected group. 
Individual group comparisons of the activity scores for each 15 
minute period (Figure 5) revealed that the MR-muscimol injected group 
was significantly more active during the first 15 minutes in the appara-
tus and throughout the remainder of the 90 minute test session. The 
activity level of the DR-muscimol injected group did not differ from 
control during the first 15 minute segment, but was significantly higher 
than control for the remainder of the test session. The hyperactivity 
induced by muscimol injections into the MR, thus, was more rapid in 
onset and of a greater magnitude, than that produced by the DR-muscimol 
injections. In fact, at the end of the 90 minute session, the cumula-
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tive activity scores of the MR-muscimol injected group was approximately 
four times greater than that of the DR-muscimol injected group. 
Conclusion 
In this first experiment we were able to confirm the report of 
Przewlocka et al. (1979) that muscimol injections into the DR produce 
hyperactivity. In addition, we found that muscimol injections into the 
MR also produced a hyperkinetic effect, and, that this effect not only 
appears earlier after injection, but is of a much greater magnitude. 
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Figure 5: Activity scores after acute muscimol injection. 
Group (Mean +/- S.E.M.) cumulative activity scores in rats 
following acute microinjection of vehicle (control, n = 10) 
, 
or muscimol into the dorsal (DR, n = 6) or median (MR, n = 
6) raphe nucleus. 
>': significantly different from control group (p<O. 01); 
1" significantly different from DR-muscimol injected group 
(p<O.Ol, Newman-Keuls' multiple range test). 
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Experiment g 
MUSCH10L DOSE-RESPONSE RELATIONSHIP IN ANIMALS 
WITH CHRONICALLY INDWELLING CANNULAE 
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In order to rule out the possible interactions of the ether 
anesthesia and the acute surgical trauma with the effects of intra-mid-
brain muscimol injections on locomotor activity, we performed a dose-
response analysis using animals having cannulae chronically implanted in 
the DR or the MR. Furthermore, since each animal served as it~ own con-
trol and received each drug dose, a complex Latin square design was 
employed in order to determine whether a given dose schedule produced 
effects significantly different from another. 
Procedure 
Beginning 1 week post-operatively, the animals were adapted to the 
test apparatus and injection procedure (Jacquet, 1975) for 3 consecutive 
days (\vednesday - Friday). The subjects were placed in the photocell 
chambers for 30 minutes, removed and wrapped in a towel for 30 - 60 sec-
onds, then returned to the chambers for an additional 2 hours. During 
the subsequent three weeks, the animals were tested Monday through Fri-
day, muscimol or vehicle injections being performed on Tuesdays and 
Thursdays. The animals were placed in the apparatus for 30 minutes and 
their activity scores recorded for each 15 minute segment. The rats 
then were removed, wrapped in a towel, and injected (on drug days only) 
over 30 seconds with 0. 5 1-11 of drug solution. The animals then were 
placed back in the chambers for an additional 2 hours. Activity counts 
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were recorded 15, 30, 60, 90 and 120 minutes post-injection. Muscimol 
(0, 25, 50, 100, 200 and 400 ng in 0.5 ~1 saline) was injected into the 
MR or the DR according to a complex Latin square design (Bruning and 
Kintz, 1977, pp. 92 - 106), with at least 10 animals receiving each of 
the 6 dose sequences. 
Results 
Histological analysis 
Prior to performing any statistical analyses of the behavioral 
data, we screened the cannula placements. Of the 60 animals implanted 
with MR cannulae, 30 were found acceptable. The cannulae in these ani-
mals terminated within the B-8 5-HT cell group coinciding with the cau-
dal linear and median raphe nuclei, just dorsal to the interpeduncular 
nucleus. The histological appearance of the cannula placements in these 
animals was similar to the needle tracts obtained in Experiment I (see 
Figure 3). The cannula tips of the rats rejected from the study termi-
nated at least 1. 5 mm lateral, dorsal, and/or caudal to the B-8 5 -HT 
perikarya. 
Of the 72 rats which were implanted with DR cannulae, only 30 had 
acceptable placements. The cannula tips in these animals all were 
localized within the boundaries of the DR (B-7 5-HT cell group). The 
cannulae in the animals eliminated from the study terminated at least 
0.75 mm dorsal and/or lateral to the DR. The histological appearance of 
the DR cannula tracts was indistinguishable from that of the DR needle 
tracts obtained in Experiment I (see Figure 4). 
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Activity level 
An ANOVA of the activity scores per 15 minutes for the 30 minute 
pre-drug session on each of the 6 drug days showed that there were no 
significant cannula placement, days, or interaction effects. There was 
a significant time effect [F(1,58)=63.20, p<0.001] due to the greater 
activity of the animals during the first 15 minutes of the 30 minute 
pre-drug period. These results show that the animals' activity levels 
were comparable during the pre-drug sessions on each of the 6 drug days. 
Subsequently, a complex Latin square analysis of the total 120 minute 
post-injection activity scores was performed. This analysis revealed a 
significant overall effect of placement site [F(1,48)=5.04, p<0.05], a 
significant overall effect of the muscimol dose [F(5,240)=29.08, 
p<0.0001], and a significant interaction between dose and injection site 
[F(5,240)=22.21, p<0.0001]. Importantly, the effects of order of treat-
ment were not significant. 
As shown in Figure 6, injections of muscimol (50 - 400 ng) into 
the MR produced significant increases in activity. The peak effect was 
seen after the 100 ng dose. In contrast, only the two highest doses of 
muscimol (200 and 400 ng) induced hyperactivity following injection into 
the DR. The temporal effects of intraraphe muscimol inj actions are 
shown in Figure l For clarity, only the data are presented which were 
obtained following the saline injections and following the doses of mus-
cimol which produced optimal effects (Figure 6) after injection into 
either the MR (100 ng) and DR (200 ng). The muscimol-induced hyper-
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Figure 6: Dose-activity effects of intra-raphe muscimol. 
Total activity scores (Mean +j- S.E.M.) for the 2 hour 
period following muscimol injections via chronically 
indwelling median (MR, n = 30) or dorsal (DR, n = 30) raphe 
cannulae. The muscimol was administered according to a 
Latin square design with 5 animals receiving each of the 
dose sequences. 
•': significantly higher than control condition (p<O.Ol, 
Newman-Keul's multiple range test); 
t significantly higher than OR-injected group (p<O.OOOl), 
# significantly higher than MR-injected group (p<O.OOOl, F-
test for simple effects). 
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Figure 7: Temporal effects of intra-raphe muscimol 
injections. 
Cumulative activity scores (Mean +j-S.E.M.) 15, 30, 60, 90 
and 120 minutes following the injection of opitmal doses of 
muscimol through cannulae chronically implanted in the 
median (MR - 100 ng, n = 30) or the dorsal (DR - 200 ng, n = 
30) raphe nucleus. The MR- and DR-saline scores were those 
obtained following saline (0.5) pl injections. 
* significantly elevated over corresponding saline-injected 
control condition (p<O. 01, Newman-Keuls' test for related 
measures); 
t significantly elevated over DR-muscimol (200 ng) injected 
condition (p<O.OS, Newman-Keuls' multiple range test). 
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activity was most prominent during the first 30 minutes post-injection, 
and diminished in magnitude over the subsequent 90 minutes. 
Conclusion 
These observations indicate that injection of muscimol into the MR 
produces a significant elevation in activity level at a dose (SO ng) 
one-fourth that required to produce a similar effect when injected into 
the DR. The magnitude of the hyperkinetic effect following the injec-
tion of an optimal (100 ng) dose of muscimol into the MR, moreover, is 
at least 1.5 times greater than after such an injection of an optimal 
dose (200 - 400 ng) into the DR. These results suggest the possibility 
that the hyperkinetic effect of muscimol following injection into the DR 
may be due to diffusion of the drug to an effective MR site. 
Inasmuch as the MR proved to be more sensitive to muscimol than 
the DR, we decided to concentrate our subsequent efforts on the MR site. 
Furthermore, since we found in Experiment II that ~he order of adminis-
tration of the drug treatments did not significantly affect the experi-
mental outcome, we also decided to employ the more cost-effective ran-
domized block designs (Kirk, 1968) in our subsequent experiments. 
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Experiment III 
INTERACTIONS OF PERIPHERAL BICUCULLINE AND CHLORDIAZEPOXIDE 
WITH INTRA-RAPHE INJECTIONS OF MUSCIMOL 
In the previous two experiments it was shown that intra-raphe 
injections of muscimol produce hyperactivity as measured in photocell 
chambers. If the hyperkinetic effect of muscimol is due to the activa-
tion of GABA receptors, then this effect should be attenuated by the 
peripheral administration of the GABA receptor antagonist, bicuculline, 
and potentiated by the facilitator of GABA-ergic neurotransmission, 
chlordiazepoxide. It was the objective of the present experiment to 
test these hypotheses. 
In a preliminary study (Sainati and Lorens, 1981) we determined 
that chlordiazepoxide, when administered intraperitoneally in doses 
greater than 3.8 mg/kg produced decreases in locomotor activity as mea-
, 
sured in dark photocell chambers. Following these doses, the animals 
appeared ataxic and sedated. Doses ranging between 1.2 - 3.8 mg/kg did 
not affect activity as compared to control. We also found that the 
intraperitoneal injection of bicuculline in doses ranging between 0.1 -
1.1 mg/kg had no effect on activity level. Higher doses regularly pro-
duced seizures, the convulsant dose for 50 percent of the cases (ED-50) 
being 2.2 mg/kg. In the following experiment, therefore, the 3.8 mg/kg 
dose of chlordiazepoxide, and the 1. 1 mg/kg dose of bicuculline were 
used. 
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Procedure 
Cannulae were implanted in the MR of 18 animals as described in 
the Materials and Methods section (Chapter II). Groups of 9 rats each 
were assigned to the studies of the chlordiazepoxide-muscimol interac-
tion, and of the bicuculline-muscimol interaction. The testing proce-
dure was identical to that described in Experiment II, except that the 
activity counts were recorded every 15 minutes for only one hour post-
injection. 
Fifteen minutes prior to receiving muscimol (0, 25, or 50 ng) 
injections into the MR, one group of rats received either saline (1.0 
ml/kg) or chlordiazepoxide (3.8 mg/kg) intraperitoneally. Fifteen 
minutes prior to receiving intra-raphe muscimol (0, 50, or 100 ng), the 
other group of rats received either the acidified vehicle (1.0 ml/kg) or 
(+)-bicuculline (1.1 mg/kg) intraperitoneally. 
A repeated measures - two factors ANOVA design was used in the 
statistical analysis of the behavioral data. This is an analysis which 
can be used when all treatments in a two-factor experiment are adminis-
tered to each subject (Bruning and Kintz, 1977, pp. 48-54). The effects 
of each treatment can be discerned individually, and the interaction 
between· the two can be ascertained. Because no statistical test for 
simple effects exists specifically for the repeated measures - two fac-
tors ANOVA design, individual comparisons between means were made with 
Studnet's t-test for related measures (Student, 1927; Bruning and Kintz, 
1977, pp. 13-16). 
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Results 
Histological analysis 
Two rats were eliminated from the chlordiazepoxide-muscimol study 
and one rat was eliminated from the bicuculline-muscimol study prior to 
statistical analysis of the behavioral data, since the cannula place-
ments in these animals were localized 1. 5 mm lateral to the MR. The 
cannula tips in the accepted animals terminated in the B-8 5-HT cell 
group dorsal to the interpeduncular nucleus. 
Locomotor activity 
Chlordiazepoxide-Muscimol Interaction. An ANOVA of the total 60 
minute post-injection activity scores failed to demonstrate a signifi-
cant effect of chlordiazepoxide alone. The effect of muscimol, however, 
was significant [F(2,16)=7.37, p<O.Ol], as was the muscimol- chlordia-
zepoxide interaction [F(2,16)=6.30, p<O.Ol]. Thus, as shown in Figure 
8, the parenteral injection of chlordiazepoxide potentiated the effect 
of intra-raphe muscimol (25 and 50 ng) on locomotor activity. 
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Figure 8: Chlordiazepoxide potentiates the muscimol effect. 
Total activity sc.ores (Mean +/- S.E.H.) for the one hour 
period following the injection of muscimol (0, 25 or 50 ng) 
into the median raphe nucleus (n = 7). Fifteen minutes 
prior to receiving muscimol, the animals received either 
chlordiazepoxide (3. 8 mg/kg) or saline (1. 0 ml/kg) 
intraperitoneally. 
,-: significantly greater than the corresponding control 
condition (p<O.Ol); 
1 significantly higher than the corresponding saline plus 
muscimol effect (p<O.OS, Students t-test, 2-tailed). 
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Bicuculline-Muscimol Interaction. An ANOVA of the total 60-minute 
post-injection activity scores failed to show a significant effect of 
bicuculline by itself. However, the effect of muscimol was significant 
[F(2,16)=8.64, p<0.005], as was the bicuculline - muscimol interaction 
[F(2,16)=6.69, p<0.05]. Figure 9 depicts the blockade of the 
hyperkinetic effect of intra-raphe muscimol (50 and 100 ng) by the 
peripheral administration of bicuculline. 
Conclusion 
These results support the view that the hyperkinetic effect of 
intra-raphe muscimol injection is due to an activation of GABA recep-
tors. 
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Figure 9: Bicuculline blocks the muscimol effect. 
Total activity scores (Mean +/- S.E.M.) for the one hour 
period following injection of muscimol (0, 50, or 100 ng) 
into the median raphe nucleus (n = 8). Fifteen minutes 
prior to receiving muscimol the animals received either 
bicuculline (1.1 mg/kg) or acidified vehicle (1.0 ml/kg) 
intraperitoneally. 
'" significantly higher than corresponding vehicle-injected 
control condition (p<0.01); 
t significantly lower than corresponding vehicle plus 
muscimol effect (p<0.002, Student's t-test, 2-tailed). 
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Experiment IV 
In Experiment III it was shown that the peripheral injection of 
chlordiazepoxide potentiated, whereas the systemic administration of 
bicuculline blocked, the hyperactive effect of intra-raphe muscimol. 
These data support the view that the hyperkinetic effect of intra-raphe 
muscimol is due to the activation of GABA receptors. However, since 
GABA and benzodiazepine receptors are localized throughout the neuraxis, 
we cannot be certain that the effects of bicuculline and chlordiazepox-
ide are due to their binding allosterically to the same GABA receptors 
as those occupied following the intra-raphe injection of muscimol. In 
order to determine whether the effects of peripherally-administered 
bicuculline and chlordiazepoxide are due to their interaction with mus-
cimol at the same receptor sites, we performed the following series of 
experiments: a) an intra-raphe benzodiazepine dose-response analysis; 
b) an intra-raphe bicuculline dose-response analysis; c) a test of the 
interactions between intra-raphe benzodiazepines and muscimol; and, d) a 
test of the interactions between intra-raphe bicuculline methiodide and 
muscimol. 
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IVa: 
INTRA-RAPHE BENZODIAZEPINE DOSE-RESPONSE ANALYSIS 
There is a substantial amount of evidence which indicates that 
GABA serves as a neurotransmitter in both the DR (Gallager, 1978; Nano-
poulos ~ al., 1980) and the MR (Forchetti and Meek, 1981). The benzo-
diazepines, moreover, are thought to act by facilitating GABA-ergic neu-
rotransmission (Gallager, 1978; Costa and Guidotti, 1979). We 
hypothesized, therefore, that intra-raphe injections of benzodiazepines 
also should produce hyperactivity by facilitating the effects of endoge-
nously released GABA. 
Procedure 
Three water soluble benzodiazepines (chlordiazepoxide, midazolam 
and flurazepam) were chosen for intra-raphe dose-response analysis. 
Cannulae were implanted in the MR of 18 rats as described in the Materi-
als and Methods section (Chapter II). Six of the rats were assigned to 
the chlordiazepoxide group, six to the midazolam group, and six to the 
flurazepam group. The subjects were tested using the same procedure as 
in Experiment II. Activity counts were recorded 15 and 30 minutes 
before and 15, 30, 60, 90 and 120 minutes after injection. On drug 
days, animals received saline or a dose of the appropriate benzodiaze-
pine (0, 0.22, 0.44, 0.88 or 1.75 nmole). A three-factor split-plot 
ANOVA with repeated measures on two factors (Kirk, 1968; Bruning and 
Kintz, 1977, pp. 73-88) was used to analyze the results of this experi-
ment. 
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Results 
Histological analysis 
The behavioral data from 2 rats (one from the chlordiazepoxide 
group and one from the midazolam group) were eliminated prior to statis-
tical analysis, since the cannula tips in these animals were localized 
1.0 - 2.0 mm lateral to the MR. The cannula tips in the accepted ani-
mals terminated in the rostral portion of the B-8 5-HT cell group, dor-
sal to the interpeduncular nucleus. 
Locomotor activity 
An ANOVA of the behavioral data demonstrated differences in the 
response to the three drugs [F(2,15)= 20.25, p<0.0002]. The effects of 
the different drug doses also were significant [F(5,75)=13.79, 
p<O. 0001]. The subjects' performances changed as a function of time 
after injection. [F(3,45)=668.26, p<0.00001]. In addition, the drug 
and dose [F(10,75)=4.08, p<0.0005], the drug and time [F(6,45)=31.19, 
p<O.OOOl], the dose and time [F(15,225)=7.64, p<0.0001], and the drug, 
dose and time [F(30,225)=4.01, p<0.0001] interactions all were signifi-
cant. Individual comparisons demonstrated that injections of flurazepam 
and midazolam into the MR produced a dose-dependent elevation in locomo-
tor activity (Figure 10). Flurazepam was· twice as potent as midazolam, 
the former having a peak effect at 0.44 nmole, the latter at 0.88 nmole. 
Chlordiazepoxide was without effect. As shown in Figure 11, the benzo-
diazepine-induced hyperactivity was most prominent during the first 30 
minutes post-injection. 
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Figure 10: Intra-raphe benzodiazepine dose-response 
relationship. 
Total activity scores (Mean +/- S.E.M.) for the 2 hour 
period following injection of 0, 0.22, 0.44, 0.88 or 1. 75 
nmole of flurazepam (FLU; n = 6), midazolam (MID; n = 5) or 
chlordiazepoxide (CDP; n = 5) through cannulae chronically 
implanted in the median raphe (MR) nucleus. 
Asterisks indicate significant elevation over the 
corresponding saline-injected control (dose = 0) condition 
('"'p<0.05, '"''•p<O.Ol, Newman-Keuls' multiple range test). 
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Figure 11: Temporal effects of intra-raphe benzodiazepines. 
Cumulative activity scores (Mean+/- S.E.M.) 15, 30, 60, 90 
and 120 minutes following the injection of optimal doses of 
flurazepam (FLU, 0.44 nmole); midazolam (MID, 0.88 nmole); 
or chlordiazepoxide (CDP, 0.44 nmole) through cannulae 
chronically implanted in the median raphe nucleus. For the 
sake of clarity, the post-saline control (CONT.) scores for 
the 3 groups have been combined. 
;b': significantly elevated over the corresponding saline-
injected control condition (p<O.Ol, Newman-Keuls' test for 
related measures). 
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Conclusion 
Facilitation of midbrain GABA neurotransmission by intra-~ffi injec-
tions of the benzodiazepines, flurazepam and midazolam, led to an 
increase in locomotor activity. Although qualitatively similar to the 
effects of intra-MR muscimol, the magnitude and duration of the benzo-
diazepine effects were somewhat less. This is not surprising, however, 
since the effects of the benzodiazepines depend on the release of 
endogenous GABA, whereas muscimol, as a receptor agonist, does not. The 
effective pharmacological doses of muscimol no doubt produce a greater 
concentration of receptor ligand than does the amount of GABA normally 
available for release. 
Interestingly, in contrast to midazolam and flurazepam, chlordia-
zepoxide failed to alter activity level following its injection into the 
HR. This observation supports the view that chlordiazepoxide is a pro-
~ 
drug, similar to prazepam and chlorazepate, which must be oxidized in 
vivo to produce a centrally active metabolite (Johnson and Rising, 1980; 
Breimer et al., 1980). Recent autoradiographic studies in our labora-
tory (Sainati et al., 1982) support this conclusion. Briefly, we found 
that both midazolam and flurazepam displaced the binding of 
3 H-flunitrazepam from brain stem tissue sections in vitro. 
----
Chlordiaze-
poxide, however, failed to do so. It would appear, therefore, that 
chlordiazepoxide itself is not active at CNS benzodiazepine receptor 
sites. 
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IVb: 
INTRA-RAPHE BICUCULLINE DOSE-RESPONSE ANALYSIS 
Procedure 
Because the free base form of bicuculline must be dissolved in a 
vehicle too acidic for direct intracranial injections, this experiment 
was performed with the water-soluble salt, bicuculline methiodide. 
Seven rats were outfitted with chronically indwelling cannulae in the 
MR. Animals were tested· as described in the procedure for Experiment 
II. On drug days, subjects received intracranial injections of either 
saline or bicuculline methiodide (0.22, 0.44 or 0.88 nmole; 81, 161 or 
323 ng as the base) according to a randomized block design. 
Results 
Histological analysis 
Of the 7 rats tested, only 5 were found to have acceptable cannula 
placements. The cannula tract and tip locations in these rats were 
indistinguishable from those in the previous experiments, as they termi-
nated within the B-8 5-HT cell group dorsal to the interpeduncular 
nucleus. 
Locomotor activity 
A two-factor split-plot ANOVA with repeated measures on one factor 
(Kirk, 1968; Bruning and Kintz, 1977, pp. 55-61) failed to reveal a sig-
nificant effect of bicuculline methiodide on locomotor activity. Only 
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the time after injection effect was significant [F(4,96)=22.24, 
p<O.OOOl]. Seizures were not observed in any of the animals following 
the administration of the bicuculline doses used. 
Conclusion 
If direct activation of GABA receptors (as produced by muscimol) 
or facilitation of GABA-ergic transmission (such as produced benzodiaze-
pines) in the ~IR results in hyperactivity, then blockade of GABA recep-
tors should have the opposite effect. The data obtained in the present 
experiment, however, do not support this view. Intra-MR muscimol may 
inhibit the firing rates of local 5-HT neurons. According to the pre-
sent hypothesis, the resultant decrease in neurotransmitter release from 
MR 5-HT efferent nerve terminals would result in the observed hyperkine-
sis. Blockade of the inhibitory effects of endogenously released GABA 
at the same receptor sites (that is, on serotoninergic neurons), 
nevertheless, may not result in the opposite condition: although it is 
possible that MR 5-HT perikarya may increase their rate of discharge 
immediately following their release from a tonic GABA-ergic inhibition, 
this enhancement most likely would be followed by an almost immediate 
return (within a fraction of a second) to the baseline due to collateral 
feedback inhibition (Aghajanian and Wang, 1978). Any transient increase 
in 5-HT release from MR efferent nerve terminals would, thus, not be of 
long enough duration to bring about a hypokinetic response. 
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IVc: 
INTERACTIONS OF INTRA-RAPHE BENZODIAZEPINES WITH MUSCIMOL 
Procedure 
Cannulae were implanted in the MR nuclei of 14 rats as described 
in the Materials and Methods section (Chapter II) Seven rats were 
assigned to the flurazepam - muscimol group and 7 to the midazolam -
muscimol grQup. In this experiment, animals received either saline veh-
icle, or a sub-effective dose (0. 22 nmole) of flurazepam or midazolam 
into the MR 5 minutes prior to the administration either of saline (0. 5 
~1) or of a sub-effective dose of muscimol (0.22 nmole). Otherwise, the 
procedure was the same as that in Experiment II. 
A repeated measures - two factors ANOVA design was used for the 
statistical analysis of the behavioral data (Bruning and Kintz, 1977, 
pp. 48-54). 
Results 
Histological analysis 
The behavioral data from 3 rats were eliminated prior to statisti-
cal analysis, since the cannula placements in these animals were local-
ized 1.5 - 2.5 mm lateral to the MR. The cannula tips terminated in the 
B-8 5-HT cell group dorsal to the interpeduncular nucleus in the 5 rats 
comprising the flurazepam - muscimol group, and in the 6 rats forming 
the midazolam - muscimol group. 
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Locomotor activity 
Flurazepam-muscimol interaction. An ANOVA of the total 2 hour 
post-injection activity scores demonstrated significant effects both of 
muscimol [F(1,26)=187.73, p<0.0001] and of flurazepam [F(1,26)= 173.38, 
p<0.0001]. The effects of flurazepam and muscimol, moreover, interacted 
[F(1,26)=161.00, p<0.0001]. Individual comparisons, however, showed 
that only the combined injection of flurazepam and muscimol produced 
significant elevations over the vehicle-injected control condition 
(Table 1). This observation accounts for the significant effects of 
muscimol and flurazepam mentioned above. 
Midazolam-muscimol interaction. An ANOVA of the total 2 hour 
post-injection activity scores demonstrated significant effects both of 
muscimol [F(1,27)= 168.06, p<0.0001] and of midazolam [F(1,27)=137.64, 
p<O. 0001]. Similar to the results above, the effects of midazolam and 
muscimol interacted [F(1,27)=165.76, p<0.0001]. Individual comparisons 
showed that only the sequential injections of midazolam and muscimol 
together produced activity scores significantly higher than those after 
vehicle injections (Table 1). This observation accounts for the signi-
ficant effects of muscimol and midazolam reported above. 
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TABLE 1 
Interaction of intra-raphe benzodiazepines with muscimol. 
Total activity scores (Mean+/- S.E.M.) following injection 
of muscimol (0.22 nmole) or saline (0.5 Jll) through cannulae 
chronically indwelling in the median raphe nucleus. Five 
minutes prior to receiving muscimol, the animals were 
injected with flurazepam (0.22 nmole; n = 5), midazolam 
(0.22 nmole; n = 6) or saline (0.5 pl). 
TOTAL 2-HOUR POST-INJECTION ACTIVITY SCORES 
DOSE 
BENZODIAZEPINE 
FLURAZEPAM 
VEHICLE 
FLURAZEPAM 
0.22 NMOLE 
MIDAZOLAM 
VEHICLE 
MIDAZOLAM 
0.22 NMOLE 
DOSE MUSCIMOL 
VEHICLE 0.22 NMOLE 
1848 ± 175 2251 ± 366 
2078 ± 174 5769 ± 392* 
1200 ± 182 1201 ± 165 
1006 ± 95 5530 ± 126t 
* Significantly different from muscimol vehicle plus 
flurazepam vehicle condition (p<0.001); 
t Significantly different from muscimol vehicle plus 
midazolam vehicle condition (p<0.001, Student's t-
test, 2-tailed). 
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Conclusion 
Our previous dose-response analysis (Experiment II) had demons-
trated that muscimol in a dose of 0. 22 nmole (25 ng) did not produce 
significant elevations in activity level. The 0.22 nmole dose of either 
flurazepam and midazolam also was below that required to induce hyperac-
tivity (Experiment IVa). However, when the subeffective dose (0. 22 
nmole) of muscimol was injected immediately following the intra-raphe 
administration of either benzodiazepine, a hyperkinetic effect was pro-
duced which was of the same magnitude as that of a four-fold higher dose 
(0. 88 nmole) of muscimol alone, as illustrated in Figure 12. These 
observations support the conclusion that the benzodiazepines act by 
facilitating the post-synpatic effects of endogenously released GABA and 
of GABA agonists. 
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Figure 12: Interaction of intra-raphe benzodiazepines with 
muscimol 
Cumulative activity scores (Hean +/- S.E.M.) 15, 30, 60, 90 
and 120 minutes following injection of muscimol (0.22 nmole) 
or saline (0. 5 J.ll) through cannulae chronically indwelling 
in the median raphe nucleus. Five minutes prior to 
receiving muscimol, the animals were injected with 
flurazepam (0.22 nmole; n = 5), midazolam (0.22 nmole; n = 
6) or saline (0.5 pl). The vehicle-muscimol 0.88 nmole data 
were obtained in Experiment IVd, which was conducted at the 
same time as the present experiment. The control means (+/-
S. E. M.) were obtained in the same manner as reported in 
Figure 11. 
'b<: significantly elevated over the corresponding saline-
injected control condition (p<O.Ol, Newman-Keuls' test for 
related measures). 
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IVd: 
INTERACTIONS OF INTRA-RAPHE BICUCULLINE METHIODIDE 
AND MUSCIMOL 
Procedure 
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Cannulae were implanted in the MR nuclei of 7 rats as described in 
the Materials and Methods section (Chapter II). In this experiment, 
animals received either saline vehicle or bicuculline methiodide (0.88 
nmole; 323 ng) into the MR 5 minutes prior to either muscimol (0. 88 
nmole; 100 ng) or saline injection. The procedure otherwise was identi-
cal to that employed Experiment II. 
Results 
Histological analysis 
Of the 7 rats studied, 6 were found to have acceptable cannula 
placements in the rostral MR. 
Locomotor activity 
An ANOVA of the total 2 hour post-injection activity scores 
demonstrated that the effect of muscimol was significant 
[F(1,27)=814.13, p<O.OOOl], whereas that of bicuculline methiodide alone 
was not. Furthermore, the effects of bicuculline methiodide and musci-
mol interacted [F(1,27)=238.87, p<O.OOOl]. As shown in Table 2, 
intra-MR bicuculline methiodide completely blocked the hyperactivity 
produced by a subsequent injection into the MR of an equimolar dose of 
muscimol. 
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Conclusion 
The results from Experiments IV a - d suggest that the effects of 
peripheral administration of benzodiazepines and bicuculline on intra-
raphe muscimol-induced hyperactivity probably are due to their interac-
tions at the same GABA receptors within the midbrain. 
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TABLE 2 
Intra-raphe bicuculline interactions with muscimol. 
Total activity scores (Mean +/- S.E.M.) for the 2 hour per-
iod following the injection of muscimol (0. 88 nmole) or 
saline (0. 5 }11) through cannulae chronically implanted in 
the median raphe nucleus (n = 6). Five minutes prior to 
receiving muscimol or saline, the animals received bicucul-
line methiodide (0.88 nmole) or saline. 
TOTAL 2-HOUR POST-INJECTION ACTIVITY SCORES 
DOSE 
BICUCULLINE 
METHIODIDE 
VEHICLE 
0.88 NMOLE 
DOSE MUSCIMOL 
VEHICLE 0.88 NMOLE 
1638 ± 224 5210 ± 246* 
1715 ± 235 1827 ± 103 
* Significantly different from muscimol vehicle 
plus bicuculline vehicle condition (p<0.001, 
Student's ~-test, 2-tailed). 
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Experiment Y.. 
MUSCIMOL DOSE-RESPONSE CURVE IN ANIMALS WITH LESIONS 
OF THE VENTRAL TEGMENTAL NUCLEI OF GUDDEN 
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In vitro autoradiographic studies have demonstrated that whereas 
the DR and MR are sites of only moderate benzodiazepine binding, the 
ventral tegmental nuclei of Gudden (VTG) show extremely dense benzo-
diazepine labelling. (Young and Kuhar, 1980; Young ~ al., 1981). 
Since the benzodiazepines are thought to bind allosterically to a mem-
brane complex including the GABA receptor, there is a correlation bet-
ween the loci of benzodiazepine and GABA binding sites. The VTG, in 
contrast t9 the DR and MR, are devoid of 5-HT perikarya (Steinbusch, 
1981; Kulmala and Lorens, 1982). Bilateral electrolytic lesions of the 
VTG result in increased open field locomotor activity (Lorens et al., 
1975). In contrast, 5, 7-dihydroxytryptamine lesions of the ascending 
serotonin pathways do not affect activity level in the open field (Lor-
ens et al., 1976; Lorens, 1978). Since the VTG lie immediately dorsola-
teral to the MR, it is possible that the locomotor effects of muscimol 
injections into the MR may be due to diffusion to the VTG. Activation 
of GABA receptors located on VTG neurons could result in hyperpolariza-
tion and suppressed rates of firing. This transient inhibition, or 
"functional lesion," could lead to locomotor hyperactivity. We, there-
fore, ablated the VTG electrolytically in order to determine whether or 
not this manipulation would affect the dose-response relationship for 
muscimol. 
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Procedure 
Three groups of animals were employed. One sham-operated control 
group of 8 animals was anesthetized, the scalps incised and retracted, 
and craniotomies performed. The lesion electrode was not lowered into 
the brain, nor were intracranial cannulae implanted. In the other 2 
groups, electrolytic VTG lesions (n = 15) were produced or sham-opera-
tions (n = 8) were performed first; immediately thereafter MR cannulae 
were implanted as described in the Materials and Methods section (Chap-
ter II). Behavioral testing began 2 weeks later. Since bilateral elec-
trolytic destruction of the VTG has been reported to produce hyperactiv· 
ity in the open field and to facilitate acquisition of a. two-way 
(shuttlebox) conditioned avoidance task (Lorens et al., 1975; 1976), 
these two tests were used to screen the animals behaviorally for effec· 
tive VTG lesions prior to the initiation of the intra-raphe muscimol 
study. Thus, only lesion animals with both open field activity scores 
and total avoidance responses above control range subsequently were 
tested for a muscimol dose-response relationship in the photocell activ-
ity cages. In addition, the locus and effectiveness of the VTG lesions 
were assessed histologically and biochemically as described previously 
(Lorens et al., 1975). 
Open field activity 
Open field activity was tested in a 100 x 100 em arena with 40 em 
high walls. Illumination was provided by a 15-watt bulb centered 120 em 
above the arena. The floor of the open field was painted white and 
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divided by black lines into 25 equal squares. Animals naive to the 
apparatus were placed in the center square at the start of the test. 
Crossings from square to square with all four limbs were recorded by the 
experimenter at 3 minute intervals for 9 minutes. 
Two-way conditioned avoidance 
Rats were trained to avoid footshock in a 100 em long, 24 em wide 
and 30 em high shuttlebox illuminated with a 40-watt fluorescent tube 
mounted outside the rear wall. The front wall was composed of clear 
Plexiglas, while the remaining surfaces were of translucent white Flex-
iglas. The test chamber was divided by a 7.5 em high metal hurdle into 
two equal sized compartments. Each side of the chamber contained a grid 
floor connected by a selector switch to a Grayson-Stadler model 
E-1064-GS shocker and scrambler. A 4 ohm speaker was mounted in each 
wall for the delivery of a 75 decibel white noise conditioned stimulus 
(CS). The ambient noise level approximated 50 -55 decibels. 
Acquisition of the two-way avoidance resP,onse was examined begin-
ning 7 days after completion of open field testing. A single session of 
50 massed trials was given to each VTG lesion animal which was hyperac-
tive in the open field, and to each cannulated and non-cannulated con-
trol animal. The first training trial started 3 minutes after the rat 
was placed in one of the compartments. The intertrial interval was 30 -
45 seconds. The CS was terminated when the rat crossed into the oppo-
site compartment. The unconditioned stimulus, a 0.8 milliampere conti-
nuous footshock, was administered if the animal failed to cross the bar-
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rier within 5 seconds after CS onset. Intertrial barrier crossings were 
recorded, but not punished. Escape and avoidance latencies were mea-
sured with a stopwatch. 
Muscimol dose-response 
analysis 
Beginning 1 week after completion of two-way avoidance testing, 
the animals were tested for locomotor activity in the photocell chambers 
using a procedure identical to that described in Experiment II, with the 
exception that activity levels were recorded every 15 minutes for only 
one hour post-injection. The doses of muscimol employed were 0, 50, 100 
and 200 ng. 
Results 
Histological analysis 
Of the 15 animals on which both VTG lesions and MR cannulations 
were performed, only 10 that met the behavioral criteria for effective 
VTG lesions and included in the drug study. Of these, only 6 had well 
placed cannulae in the B-8 5-HT cell group dorsal to the interpeduncular 
nucleus (Figure 13) and subsequently were analyzed behaviorally and bio-
chemicaly. Since the cannula placements in the 8 control animals were 
similar to those in the accepted lesion subjects, none of these animals 
was rejected from the study. 
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Figure 13: VTG lesion and MR cannula placement sites. 
Reconstruction of damage (blackened area) in the VTG lesion 
rats. Black circles with arrows indicate loci of cannula 
tips. Numbers identify individual animals. 
Abbreviations: cniV = trochlear nucleus, dr =dorsal raphe 
nucleus, dtg = dorsal tegmental nucleus of Gudden, ipn = 
interpeduncular nucleus, mr = median raphe nucleus, vtg = 
ventral tegmental nucleus of Gudden; DBC = decussation of 
brachium conjunctivum, ML = medial lemniscus, MLF = medial 
longitudinal fasciculus. 
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Biochemical analysis 
The striatal and hippocampal concentrations of 5-HT and its meta-
bolite, 5 -HIAA, were assayed by HPLC. The following groups were com-
pared: the animals with acceptable VTG lesions and MR cannulae (n = 6), 
the sham-operated animals with MR cannulae (n = 8), and the sham-oper-
ated non-cannulated controls (n = 8). As shown in Table 3, hippocampal 
5-HT levels in the VTG lesion animals were significantly reduced in com-
parison with both the sham-operated controls (57%) and the MR cannulae 
implanted controls (52%). The hippocampal 5-HIAA levels in the VTG 
lesion rats showed similar reductions. In contrast, the striatal 5-HT 
concentrations of the 3 groups did not differ significantly. The stria-
tal 5 -HIAA level in the VTG lesion rats, however, was significantly 
lower (18%) than the control level. These observations are in agreement 
with those reported by Lorens and coworkers (1975). Importantly, the MR 
cannula placements by themselves did not significantly affect the con-
centration of 5-HT in either the hippocampus or the striatum. Although 
the hippocampal 5-HIAA level of the sham-operated MR cannulated rats was 
slightly but significantly lower than control (24%), these data suggest 
that the MR cannulae did not significantly damage the 5-HT perikarya 
comprising, or the 5-HT fibers emanating from, the B-8 5-HT cell group. 
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TABLE 3 
Effects of VTG lesions on regional 5-HT and 5-HIAA levels. 
Hippocampal and striatal 5-hydroxytryptamine (5-HT) and 
5-hydroxyindoleacetic acid (5-HIAA) concentrations (Mean+/-
S.E.M. ng/g wet tissue mass) in VTG lesion and control ani-
mals. Data entries represent Mean+/- S.E.M. 
TREATMENT 
SHAM-OPERATED 
CONTROL 
MR.-CANNULA 
ALONE 
VTG LESION+ 
MR.-CANNULA 
STRIATAL AND HIPPOCAMPAL 5-HT AND 5-HIAA LEVELS 
IN VTG LESION AND NON-LESION ANIMALS 
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HIPPOCAMPUS STRIATUM 
n 
8 
8 
6 
5-HT 
(ng/g) 
416 ± 27 
370 ± 33 
179 ± 31*t 
5-HIAA 
(ng/ g) 
743 ± 55 
564 ± 30* 
343 ± 28*t 
5-HT 
(ng/g) 
607 ± 22 
600 ± 22 
619 ± 26 
5-HIAA 
(ng/g) 
937 ± 34 
898 ± 37 
767 ± 35* 
* Significantly different from sham-operated controls (p<0.01); 
t Significantly different from MR-cannula alone (p<0.01, Newman-
Keuls' multiple range test). 
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Behavioral analysis 
Open Field Activity and Conditioned Avoidance Acguitision. These 
two behavioral tests were used to screen the effectiveness of the VTG 
lesions. Only the ranges of scores obtained from the rats accepted for 
the intra-raphe muscimol dose-response analysis are presented. The 
ranges of total 9-minute open field activity scores were as follows: MR 
cannula implanted plus VTG lesion group (n = 6), 365 - 521; sham-oper-
ated MR cannula implanted group (n = 8), 128 - 298; sham-operated non-
cannulated group (n = 8), 52 - 235. The ranges for the total number of 
conditioned avoidance responses emitted during the 50 massed trials 
were: animals with VTG lesions and implanted MR cannulae, 28 - 43; 
sham-operated rats with MR cannulae, 9 - 27; sham-operated controls, 1 -
26. The group of rats with VTG lesions plus MR cannulae also tended to 
show more inter-trial spontaneous barrier crossings (2 - 248) during the 
entire test session (about 45 minutes in length) than either the non-le-
sion MR cannula implanted (0 - 22) or the sham-operated non-cannulated 
control (O - 14) groups. 
Muscimol Dose-Response Analysis. An ANOVA (three factor mixed 
design- repeated measures on two factors; Bruning and Kintz, 1977, pp. 
62 - 72) of the 30 minute pre-injection activity levels of the rats 
with VTG lesions and MR cannulae, versus the non-lesion rats with imp-
lanted MR cannulae for the 4 drug days revealed both significant group 
[F(1,10)=30.66, p<0.0005] and time [F(1,10)= 112.44, p<O.OOOl] effects. 
This latter effect was due to the greater level of activity of the ani-
mals during the first 15 minutes in the apparatus. 
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A subsequent ANOVA of the total 60 minute post-injection activity 
scores for the 4 drug days showed neither significant group nor interac-
tion effects. As expected, the dose effects were significant 
[F(3,30)=11.86, p<O.OOOl]. Muscimol produced similar dose-dependent 
elevations in activity level in both groups (Figure 14). Because the 
animals with VTG lesions evidenced higher baseline levels of activity 
than the non-lesion subjects, we reexamined the post-muscimol effects 
after taking this difference into consideration. For this purpose the 
activity scores obtained by each rat during the last 15 minutes of the 
pre-drug control period were subtracted from each of its four 15-minute 
post-injection scores. An ANOVA of these data also failed to demons-
trate any significant difference between the VTG lesion and control 
groups. As expected, the muscimol dose effect was significant [F(3,30) 
=16.68, p<0.0001], but the group-dose interaction was not. 
Conclusion 
These data suggest that the GABA and benzodiazepine receptors 
located on neuronal cell bodies or fibers within the VTG do not mediate 
the hyperkinetic effects of intra-raphe muscimol administration. 
116 
Figure 14: Effects of VTG lesions on muscimol-induced 
hyperactivity. 
Dose-response relationship for muscimol injections through 
cannulae chronically implanted in the median raphe nucleus 
of rats with bilateral lesions in the ventral tegmental 
nuclei of Gudden (VTG, n = 6) or control operations (n = 8). 
Total activity scores (Mean +j- S.E.~1.) for the one hour 
period following muscimol injection. 
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experiment VI 
MUSCU10L DOSE-RESPONSE CURVE IN ANIMALS WITH LESIONS 
OF THE ASCENDING 5-HT PROJECTIONS 
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We have found benzodiazepine binding sites in the MR, although not 
as dense as in the VTG (Sainati ~ al., 1982). Since destruction of the 
VTG had no effect on the locomotor response to intra-raphe muscimol, and 
since the peripheral administration of benzodiazepines has been reported 
to diminish 5-HT turnover in the CNS, we decided to determine the effect 
of forebrain 5-HT depletion on the effects of intra-raphe muscimol. 
Procedure 
The ascending 5-HT projections were destroyed by injecting 
5,7-dihydroxytryptamine (~,7-DHT) intracerebroventricularly (n = 12) or 
intramesencephalically (n = 12) as described in the Materials and Meth-
ods section (Chapter II). These animals, as well as vehicle-injected, 
controls, were implanted with MR cannulae during the same operative ses-
sion. Beginning 2 weeks post-operatively the animals were tested as in 
Experiment II, again with activity counts recorded every 15 minutes for 
one hour post-injection. At the end of the experiment, the animals were 
sacrificed by decapitation, their hippocampal and striatal 5-HT levels 
assayed by HPLC, and their brainstems fixed in buffered formalin for 
histological verification of cannula and mesencephalic 5,7-DHT injection 
sites. 
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Results 
Histological analysis 
Of the animals which survived the entire experiment, 7 rats which 
had been injected intraventricularly with 5,7-DHT, 7 animals which had 
received intraventricular injections of the vehicle, 7 which had been 
injected intramesencephalically with 5,7-DHT, and 6 which had been given 
vehicle injections into the mesencephalon had cannulae well localized 
within the B-8 5-HT cell group, dorsal to the interpeduncular nucleus. 
In addition, the sites of the intramesencephalic 5, 7-DHT and vehicle 
injections were ex·amined and all found to be appropriately localized 
within the course of the ascending 5-HT projections through the ventral 
tegmental area of Tsai, or immediately dorsal to the rostral tip of the 
interpeduncular nucleus (Figure 15). The histological appearance of the 
5,7-DHT and vehicle injection sites were virtually indistinguishable. 
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Figure 15: Photomicrograph of a midbrain 5,7-DHT injection 
site. 
Site of a typical intra-mesencephalic 5,7-dihydroxy-
tryptamine (5,7-DHT) injection (4.0 pg in 2.0 )11 vehicle, 
bilaterally) is demarcated by a glial scar (arrows). 
Cresylecht violet stained 50 ~m coronal section. Bar 
represents 1 mm. Abbreviations: Aq = cerebral aqueduct of 
Sylvius, IPN = interpeduncular nucleus, R =red nucleus. 
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Biochemical analysis 
The 5-HT and 5-HIAA concentrations in the neostriata and hippo-
campi of the control animals which had received intracerebroventricular 
vehicle injections (Table 4) were virtually the same as those for the 
sham-operated control animals in Experiment V (Table 3). Intraventricu-
lar 5, 7 -DHT reduced the 5 -HT concentrations in both the striatum (95%) 
and hippocampus (83%) as compared to intraventricular vehicle injec-
tions. The intramesencephalic 5, 7-DHT injections also significantly 
reduced the 5-HT contents of the striatum (77%) and the hippocampus 
(59%) as compared to the intra-midbrain vehicle injections. Similar 
reductions were seen in the regional concentrations of the 5-HT metabol-
ite, 5-HIAA. Intramesencephalic vehicle injections in comparison to the 
intraventricular vehicle injections, produced a small (22%), insignifi-
cant reduction in the hippocampal 5-HT concentration, but a significant 
(37%) fall in hippocampal 5-HIAA content (Table 2). This observation, 
supported by the histological data, suggests that the intra-midbrain 
vehicle injections interrupted some of the 5-HT fibers which innervate 
the hippocampus. 
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TABLE 4 
Effect of 5,7-DHT on regional 5-HT and 5-HIAA levels. 
Hippocampal and striatal 5-hydroxytryptamine (5-HT) and 
5-hydroxyindoleacetic acid (5-HIAA) concentrations (Mean+/-
S.E.M. ng/g wet tissue mass) in control animals and animals 
with intra-midbrain and intraventricular 5,7-dihydroxy-
tryptamine (5,7-DHT) lesions. 
STRIATAL AND HIPPOCAMPAL 5-HT AND 5-HIAA LEVELS 
IN ANIMALS WITH INTRAVENTRICULAR OR 
INTRA-MIDBRAIN 5,7-DHT LESIONS 
HIPPOCAMPUS STRIATUM 
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TREATMENT n 5-HT 5-HIAA 5-HT 5-HIAA 
(ng/g) (ng/g) (ng/g) (ng/g) 
INTRAVENTRICULAR 7 464 ± 49 741 ± 64 526 ± 61 824 ± 76 VEHICLE 
INTRAVENTRICULAR 7 76 ± 13*t§ 60 ± 18*i·§ 28 ± 6*t§ 102 ± 23*t§ 5,7-DHT 
INTRA-MIDBRAIN 
I 6 
. 362 ± 34 470 ± 62* 542 ± 99 757 ± 69 VEHICLE 
INTRA-MIDBRAIN 7 148 ± 15*§ 168 ± 41*§ 123 ± 35*§ 327 ± 54*§ 5,7-DHT 
* Significantly different from intraventricular vehicle (p<0.01); 
t Significantly different from intra-midbrain 5,7-DHT (p<O.Ol); 
§ Significantly different from intra-midbrain vehicle (p<0.01, 
Newman-Keuls' multiple range test). 
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Behavioral analysis 
An ANOVA (three factor mixed design - repeated measures on one 
factor; Bruning and Kintz, 1977, pp. 62 - 72) of the pre-drug baseline 
activity levels of the 4 groups of rats failed to reveal any significant 
5,7-DHT lesion effect, regardless of the mode of its production (intra-
ventricular versus intramesencephalic). However, an ANOVA (three factor 
mixed design - repeated measures on two factors; Bruning and Kintz, 
1977, pp. 73 - 84) of the effects of intra-raphe muscimol injections 
showed the following. The effects of the dose of muscimol were signifi-
cant [F(3,72)=6.28, p<0.002], as were the effects of time after injec-
tion {F(3,72)=14.59, p<0.0001]. In addition, the effects of lesion 
group and of muscimol dose interacted [F(9,72)=7.26, p<O.OOl]. Indivi-
dual comparisons of the total 60 minute post-injection activity level 
for each group confirmed that both types of forebrain 5 -HT-reducing 
lesion markedly attenuated the effects of intra-raphe muscimol (Figure 
16). 
Conclusion 
The data obtained from the present experiment suggest that the 
hyperkinetic effect of intra-midbrain raphe injections of muscimol 
depend on an intact ascending 5-HT fiber system. 
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Figure 16: Forebrain 5-HT depletion blocks the effect of 
muscimol. 
Dose response relationship for the injection of muscimol (0, 
50, 100 or 200 ng) through cannulae chronically implanted in 
the median raphe nucleus of rats which had received 
5,7-dihydroxytryptamine (5,7-DHT) injections into the 
cerebral ventricles (75 )lg bilaterally), or into the 
ascending 5-HT fibers at the level of the red nucleus (4.0 
J.lg bilaterally). Group mean (+/- S.E.M.) activity scores 
for the 1 hour post-injection period are presented. 
't: significantly elevated over saline-injected control 
condition (p<0.01, Newman-Keuls' test for related measures)~ 
t significantly elevated over intra-midbrain 5,7-DHT, 
§ significantly elevated over intra-ventricular 5,7-DHT, 
# significantly elevated over intra-midbrain vehicle 
(p<O.Ol, Newman-Keuls' multiple range test). 
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CHAPTER IV 
DISCUSSION 
General Discussion 
Overall, the present series of experiments indicates that the 
injection of the GABA agonist, muscimol, into the mesencephalic raphe 
results in a dose-dependent hyperkinetic response which is mediated by 
an ascending serotonergic system. The present observations also suggest 
that GABA receptors within the midbrain raphe regulate the discharge 
rate of 5-HT neurons whose forebrain efferents modulate motor systems, 
and that the benzodiazepines can modify the activity of these systems 
centrally. 
The first experiment confirmed previous findings (PrzewJocka et 
al. 1979) that acute microinjection of muscimol (100 ng) into the dorsal 
raphe nucleus produces hyperactivity as measured in photocell chambers. 
In addition, the median raphe nucleus was found to be even more sensi-
tive to muscimol (100 ng) than the dorsal raphe nucleus, the magnitude 
of the hyperkinetic effect being four times greater after injection into 
the former site. The acute injection paradigm employed by Przewtocka 
and associates (1979), and in Experiment I, required that the subjects 
be tested immediately upon awakening from the ether anesthetic. Thus, 
it was not possible to discern whether the hyperactivity produced was 
due to muscimol alone, or to the interaction between muscimol, ether and 
the trauma of surgery. 
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In order to circumvent this problem, a muscimol dose response-ana-
lysis was conducted using animals with cannulae implanted chronically 
into either the dorsal or the median raphe nucleus (Figure 5). Since 
each animal received each drug dose, this experiment used a Latin square 
design in order to determine any order of treatment effects. Accord-
ingly, injection of muscimol into the median raphe nucleus produced a 
significant elevation in activity level at one-fourth the dose (50 ng) 
required to produce a similar effect when injected into the dorsal raphe 
nucleus. The hyperkinetic response following the injection of an opti-
mal dose of muscimol (100 ng) into the median raphe nucleus, moreover, 
was at least 1.5 times more marked than the response to an injection 
(200 ng) of muscimol into the dorsal raphe nucleus (Figure 6). As there 
was no effect of order of treatment, subsequent experiments were per-
formed using a randomized block design. 
• The observed four-fold greater sensitivity of the median raphe 
nucleus as compared to the dorsal raphe nucleus raises the possibility 
that the hyperkinesis following muscimol injections into the dorsal 
raphe nucleus may be due, at least in part, to a spread of the drug to 
the more sensitive median raphe site. We have begun a series of in 
vivo autoradiographic studies to determine the time course and the 
extent of the spread of radiolabel following injections of various doses 
of 3 H-muscimol through cannulae chronically implanted in the dorsal and 
median raphe nuclei of rats. Our preliminary results suggest that fol-
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lowing injections of 3 H-muscimol (50 ng) into the median raphe nucleus, 
the greatest density of the label remains concentrated around the guide 
cannula tip, even 60 minutes post-injection. A light, but significant 
density of label, however, has spread by this time nearly 1. 0 mm ven-
trally, caudally and rostrally. Such a spread of muscimol from the tip 
of a cannula in the dorsal raphe nucleus includes the median raphe 
nucleus. It is of interest to note in this regard that PrzewJocka et 
al. (1979) fou.nd decreases in 5-HT and 5-HIAA concentrations in the 
hypothalamus, but not in the neostriatum, following the injection of 
muscimol (25 - 100 ng) into the dorsal raphe nucleus. As reviewed in 
Chapter I, substantial evidence has been advanced demonstrating that 
5-HT fibers afferent to the neostriatum arise predominantly in the dor-
sal raphe nucleus (B-7 5-HT cell group), whereas the 5-HT projection to 
the hippocampus originates principally in the B-8 5-HT cell group, which 
overlaps the caudal linear and median raphe nuclei. In addition, For-
chetti and Meek (1981) have reported that muscimol injections into the 
median raphe nucleus reduce 5-HT turnover in the hippocampus. Thus, the 
hyperkinetic response to intra-dorsal raphe muscimol injections observed 
by Przewlocka and collaborators might have been due to a spread of the 
muscimol to the median raphe nucleus (B-8 5-HT cell group). This 
hypothesis currently is under investigation in our laboratory. 
As stated earlier, several reports implicate GABA as a neurotran-
smitter in both the dorsal (Belin ~ al., 1979; Forchetti and Meek, 
1981; Gallager, 1978; Gallager and Aghajanian, 1976; Massari et al., 
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1976; Paul et al., 1981) and the median raphe nucleus (Forchetti and 
- ---.., 
Meek, 1981). Many of the behavioral and physiological effects of the 
benzodiazepines are believed to be due to their facilitation of GABA-er-
gic transmission (Cook and Sepinwall, 1975; Costa and Guidotti, 1979; 
Costa et al., 1981; Gallager, 1978; Paul et al., 1981). If the effects 
of intra-mesencephalic administration of muscimol were due to activation 
of GABA receptors in the raphe nuclei, they should be potentiated by 
benzodiazepines (for example, chlordiazepoxide) and blocked by the 
GABA-receptor antagonist, bicuculline. 
In a preliminary study (Sainati and Lorens, 1981) we found that 
intraperitoneal administration of chlordiazepoxide in doses greater than 
3.8 mg/kg produced decreases in locomotor activity as measured in dark 
photocell chambers to which the animals had been habituated previously. 
Lower doses produced no effect on activity level. These findings are 
consistent with other reports demonstrating that although the benzo-
diazepines enhance exploratory behavior in novel environments, they have 
little effect on activity level when the animals are tested in settings 
to which they have been habituated (Marriott and Spencer, 1965; Christ-
mas and Maxwell, 1970; Krsiak et al., 1970; Pieri et al., 1981). 
It was found (Experiment III) that peripheral administration of 
chlordiazepoxide, in the sub-ataxic dose of 3. 8 mg/kg, did not itself 
affect activity level, but enhanced the locomotor activity response to 
low doses (25 and 50 ng) of muscimol injected into the median raphe 
nucleus. Conversely, a subconvulsant dose of bicuculline ( 1. 1 mg/kg) 
completely blocked the response to 50 and 100 ng of muscimol. 
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If benzodiazepine compounds do act to facilitate GABA-ergic tran-
smission, it seemes plausible to hypothesize that intra-raphe adminis-
tration of representative benzodiazepines might produce increases in 
locomotor activity. We tested (Experiment IVa) this hypothesis by 
injecting three different water-soluble benzodiazepines (chlordiazepox-
ide, flurazepam and midazolam) directly into the median raphe nucleus 
through chronically indwelling cannulae. Water soluble compounds were 
chosen in order to avoid any potential behavioral effects that might 
ensue from the use of a non-aqueous vehicle. The ethanol-propylene gly-
col vehicle commonly used to dissolve non-water soluble benzodiazepines 
most likely would have deleterious ~ffects if injected directly into the 
brain. We found that injections of flurazepam and midazolam directly 
into the median raphe nucleus both produced dose-dependent increases in 
locomotor activity (Figure 10). Flurazepam, moreover, produced a maxi-
mal hyperkinetic effect at a dose one-half as great as that required for 
midazolam. This observation is consistent with the hypothesis that 
these compounds act on two different allosteric sites on a benzodiaze-
pine-GABA-receptor complex (Costa and Guidotti, 1979; Olsen, 1982). The 
greater potency of flurazepam over midazolam in inducing hyperactivity 
also is in keeping with the relative order of potencies of these drugs 
in displacing radiolabeled benzodiazepines from binding sites in vitro 
(Nohler and Okada, 1977; Braestrup and Squires, 1978; Brasetrup and 
Nielsen, 1980) . 
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The failure of chlordiazepoxide both to induce hyperactivity when 
injected into the median 
3H-flunitrazepam binding 
raphe nucleus in vivo, 
in vitro (Sainati et al., 
and to displace 
1982), is further 
evidence that chlordiazepoxide is a pro-drug which must be converted to 
active metabolites in order to have an effect in the central nervous 
system (Greenblatt and Shader, 1974; Johnson and Rising, 1979; Breimer 
et al., 1980; Harvey, 1980). 
The benzodiazepines are thought to act post-synaptically by bind-
ing at a site on a large receptor-ionophore complex allosteric to the 
GABA binding site, and thereby increase the affinity of the latter for 
its ligand. If so, then the GABA agonist, muscimol, and the centrally 
active benzodiazepines should have additive hyperkinetic effects when 
injected one after the other directly into the median raphe nucleus. 
Indeed combining a sub-effective dose of muscimol with a sub-effective 
dose of either flurazepam or midazolam produced hyperkinetic effects as 
robust as a four-fold higher dose of muscimol alone (Figure 12). 
If facilitation of GABA-ergic neurotransmission in the median 
raphe nucleus produced hyperactivity, then blockade of GABA receptors 
might be expected to have the opposite effect. However, intra-raphe 
bicuculline injections did not affect activity level. This observation 
is not surprising, since release from tonic GABA-ergic inhibition (For-
chetti and Meek, 1981) would result in an initial brief increase in the 
firing rates of 5-HT neurons, followed by an almost immediate return to 
baseline due to collateral feedback inhibition (Aghajanian and Wang, 
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1978). On the other hand, the intra-raphe injection of bicuculline did 
block the hyperkinetic effect of muscimol, providing additional evidence 
that the muscimo1 effect is due to a direct activation of GABA receptors 
within the raphe. 
The ventral tegmental nuclei of Gudden (VTG) lie just dorsolateral 
to the median raphe nucleus. Bilateral electrolytic lesions in the VTG 
produce hyperactivity similar to that seen after electrolytic lesions in 
the median raphe nucleus. The VTG are sites of dense benzodiazepine 
receptor localization (Young and Kuhar, 1980). In vitro autoradio-
graphic studies currently in progress in our laboratory confirm this 
finding (Sainati !! al., 1982). Furthermore, benzodiazepine receptors 
usually are associated with GABA receptors (Costa and Guidotti, 1979; 
Paul et al., 1981). Although not a particularly rich source of GABA or 
GAD (Nassari et al., 1976), the VTG receive a significant afferent pro-
jection from the ipsi- and contra-lateral dorsal tegmental nuclei of 
Gudden (Briggs and Kaelber, 1971; Petrovicky, 1973), which contain high 
levels of GAD. It seemed entirely possible, therefore, that the hyper-
activity induced by intra-raphe muscimol injections could be due to dif-
fusion of the drug to GABA-ceptive sites located in the VTG. We, there-
fore, destroyed the VTG in order to determine whether this manipulation 
would attenuate the hyperkinetic effect of intra-raphe muscimol injec-
tions. We found, in agreement with earlier findings (Lorens et al., 
1975), that the VTG lesions increased open field activity and facili-
tated the acquisition of a two-way conditioned avoidance response. In 
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the darkened activity chambers, the VTG lesion animals also manifested 
higher baseline levels of activity than controls, but the lesions failed 
to attenuate the facilitatory effects of muscimol. Thus , it appears 
that the effects of intra-raphe muscimol on locomotor activity and of 
VTG lesions on this behavior, are independent phenomena. 
Subsequently, forebrain 5 -HT was depleted by injecting the spe-
cific serotonin neurotoxin, 5, 7-dihydroxytryptamine, into either the 
lateral cerebral ventricles or into the midbrain tegmentum. These 
lesions markedly attenuated the locomotor response produced by muscimol 
injections into the median raphe nucleus. These data suggest that mid-
brain GABA neurons modulate activity level in the rat through a direct 
action on mesencephalic serotonergic neurons. 
As a result, we hypothesize that when muscimol is injected 
directly into the midbrain raphe nuclei, it suppresses the firing rate 
of serotonergic neurons by activating local GABA receptors. This, in 
turn, elicits locomotor hyperactivity by releasing hippocampal (Williams 
and Azmitia, 1981) or substantia nigra (see below) neurons from a tonic 
serotonergic inhibitory influence. Intraventricular and intramesence-
phalic 5,7-dihydroxytryptamine lesions, however, did not alter baseline 
activity level in our photocell chambers. Biochemical analysis showed 
that these lesions resulted in a degeneration of forebrain 5-HT effe-
rents, but histological analysis indicated that their perikarya of ori-
gin were spared, possibly because of sustaining collaterals. It may be 
that in order to induce hyperactivity the 5-HT cell bodies associated 
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with the midbrain raphe nuclei themselves must be destroyed. Also, dur-
ing the 2 week post-lesion recovery period, the motor systems of the 
animals may adapt to the loss of the ascending 5-HT projections. 
Nonetheless, the link between the midbrain GABA-ceptive site normally 
responsible for inducing hyperactivity, and the areas which control 
motor behavior still are lost. Thus, the acute inhibition of 5-HT neu-
rons following intra-raphe muscimol produces hyperactivity, whereas a 
lesion which chronically destroys ascending 5-HT projections allows a 
new, compensated "steady state" to develop. 
The neuronal mechanisms by which a GABA-ergic inhibition of raphe 
5-HT cells might produce elevations in locomotor activity is largely a 
matter of speculation. There is a substantial amount of evidence to 
support the existence of inhibitory 5-HT projections from the dorsal and 
median raphe nuclei to the substantia nigra in the rat (Dray et al., 
1976; 1978; Nicolaou et al., 1979; van der Kooy and Hattori, 1980a). 
Giambalvo and Snodgrass (1978) report that 5,7-dihydroxytryptamine 
injections into the median raphe nucleus, if placed 0. 3 mm lateral to 
the midline, produce a "unilateral" lesion. Such lesions cause rats to 
rotate in a direction contralateral to the site of injection, the rota-
tion being blocked by haloperidol. They found a significant correlation 
between the rate of rotation, the decrease in cortical 5 -HT turnover, 
and the increase in striatal dopamine turnover. Moreover, they found 
that injections of 5, 7-aihydroxytryptamine into the substantia nigra 
itself produced biochemical and behavioral changes similar to those fol-
lowing 5,7-dihydroxytryptamine injections into the median raphe nucleus. 
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The nigrostriatal dopamine pathway is an important component of 
the extrapyramidal motor system. The indirect dopamine agonist, ampheta-
mine, and the dopamine-receptor agonist, apomorphine, both can induce 
turning in rats with unilateral lesions in the nigrostriatal dopamine 
system (Ungerstedt and Arbuthnott, 1970; Ungerstedt, 1971). These 
drugs, however, induce turning in opposite directions. Amphetamine is 
thought to produce ipsilateral turning by releasing dopamine from 
intact contralateral striatal nerve terminals, while apomorphine is 
thought to induce contralateral turning by stimulation of supersensi-
tive dopamine receptors in the denervated ipsilateral striatum. 
If unilateral stimulation of striatal dopamine receptors produces 
rotation in a direction contralateral to the site of stimulation, then 
bilateral stimulation of striatal dopamine receptors might produce a 
non -rotational hyperactivity. In our experiments, midline intra-raphe 
injections of muscimol hypothetically would suppress the inhibitory 
raphe-substantia nigra 5-HT pathway, producing a bilateral increase in 
the firing rates of nigral dopamine neurons. This, in turn, would lead 
to a non-rotational, stereotypic hyperkinesis. 
In summary, the present results suggest that midbrain raphe 5-HT 
neurons exert a tonic inhibitory effect on CNS systems which influence 
locomotor behavior. Temporary removal of this inhibition by administer-
ing the GABA agonist, muscimol, or the benzodiazepines, flurazepam and 
midazolam, into the mesencephalic raphe results in hyperactivity. Thus, 
this forebrain 5-HT system appears to be regulated by raphe GABA inter-
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neurons, whose post-synaptic effects can be facilitated following the 
administration of benzodiazepine drugs. 
Proposals for Future Research 
If, as stated above, intra-raphe injections of muscimol produce 
hyperactivity by suppressing an inhibitory raphe-substantia nigra 5-HT 
pathway, then the effect of muscimol should be prevented by the adminis-
tration of a dopamine antagonist, such as haloperidol. Haloperidol 
would be expected to block the hyperkinetic effects of the hypothesized 
increased dopamine release from the nigra-striatal pathway. Further-
more, nigral lesions using 5,7-dihydroxytryptamine might produce eleva-
tions in activity level, and should prevent the hyperkinetic effect of 
intra-raphe muscimol injections. 
Although the dorsal and median raphe nuclei (Taber, 1960) contain 
serotoninergic neurons, such cells are not the sole constituents of 
these two nuclear groups (Aghajanian ~ al., 1978; Descarries ~ al., 
1979; Steinbusch et al., 1980; van der Kooy and Steinbusch, 1980; Ste-
inbusch, 1981; Kulmala and Lorens, 1982). The following series of 
experiments is proposed, therefore, to determine the relative importance 
of the 5-HT efferents from the dorsal and median raphe nuclei in the 
mediation of intra-raphe muscimol induced hyperkinesis. 
Huscimol dose response analysis will be performed in animals with 
selective 5,7-dihydroxytryptamine lesions of the dorsal or median raphe 
nucleus, as well as in subjects with combined lesions of both nuclei. 
These results will be compared to those obtained from appropriate con-
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trol animals, and to data from rats with ibotenic acid lesions of the 
dorsal and/or median raphe nucleus. Ibotenic acid is an excitotoxic 
isoxazole compound which selectively destroys neuronal cell bodies at 
the site of application while sparing axons of passage and nerve termi-
nals of extrinsic origin (Schwarcz, ~ al., 1979a; 1979b). It appears, 
moreover, that the somata of neurons which use a biogenic amine (such as 
5-HT) as a neurotransmitter are relatively resistant to the toxic 
effects of ibotenic acid (R. Schwarcz, personal communication; S.A. Lor-
ens, unpublished observations). Thus, these two neurotoxins, 
5, 7 -dihydroxytryptamine and ibotenic acid, could be used to produce 
relatively specific lesions of midbrain 5-HT· and non-5-HT·containing 
neuronal perikarya, respectively. 
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